BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. The Lancet 2020;395:2008-20. [DOI: 10.1016/s0140-6736(20)30974-0] [Cited by in Crossref: 153] [Cited by in F6Publishing: 490] [Article Influence: 76.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu H, Zhang J, Wei C, Liu Z, Zhou W, Yang P, Gong Y, Zhao Y. Prognostic signature construction of energy metabolism-related genes in pancreatic cancer. Front Oncol 2022;12:917897. [DOI: 10.3389/fonc.2022.917897] [Reference Citation Analysis]
2 Wang Y, Ji Y, Xu Q, Huang W. Prognostic N6-methyladenosine (m6A)-related lncRNA patterns to aid therapy in pancreatic ductal adenocarcinoma. Front Genet 2022;13:866340. [DOI: 10.3389/fgene.2022.866340] [Reference Citation Analysis]
3 Hoyt M, Song Y, Gao S, O'Palka J, Zhang J. Prediagnostic BMI trajectories in relation to pancreatic cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Obesity (Silver Spring) 2022. [PMID: 36156459 DOI: 10.1002/oby.23550] [Reference Citation Analysis]
4 Song Z, Wang X, Chen F, Chen Q, Liu W, Yang X, Zhu X, Liu X, Wang P. LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer. Front Oncol 2022;12:1004212. [DOI: 10.3389/fonc.2022.1004212] [Reference Citation Analysis]
5 Deng D, Patel R, Chiang C, Hou P. Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance. Cells 2022;11:2952. [DOI: 10.3390/cells11192952] [Reference Citation Analysis]
6 Zhang XP, Gao YX, Xu S, Zhao GD, Hu MG, Tan XL, Zhao ZM, Liu R. A novel online calculator to predict early recurrence and long-term survival of patients with resectable pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: A multicenter study. Int J Surg 2022;106:106891. [PMID: 36165934 DOI: 10.1016/j.ijsu.2022.106891] [Reference Citation Analysis]
7 Cui Z, Mo J, Song P, Wang L, Wang R, Cheng F, Wang L, Zou F, Guan X, Zheng N, Yang X, Wang W. Comprehensive bioinformatics analysis reveals the prognostic value, predictive value, and immunological roles of ANLN in human cancers. Front Genet 2022;13:1000339. [DOI: 10.3389/fgene.2022.1000339] [Reference Citation Analysis]
8 Xu S, Zhang XP, Zhao GD, Zou WB, Zhao ZM, Liu Q, Hu MG, Liu R. Derivation and validation of a preoperative prognostic model for resectable pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00231-4. [PMID: 36171167 DOI: 10.1016/j.hbpd.2022.09.009] [Reference Citation Analysis]
9 Zhang XP, Xu S, Zhao ZM, Liu Q, Zhao GD, Hu MG, Tan XL, Liu R. Robotic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Analysis of surgical outcomes and long-term prognosis in a high-volume center. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00228-4. [PMID: 36171169 DOI: 10.1016/j.hbpd.2022.09.006] [Reference Citation Analysis]
10 Shang L, Li P, Fan J, Zhao C, Niu X, Bian Q, Yuan Z, Kong Y, Zhu T, Xu B, Dong J, Xiang H. Case report: Two PD-L1 positive unresectable advanced pancreatic carcinoma patients with microsatellite stability achieved R0 resection after PD-1 antibody plus chemotherapy as a successful downstaging therapy: A report of two cases. Front Immunol 2022;13:946266. [DOI: 10.3389/fimmu.2022.946266] [Reference Citation Analysis]
11 Liu Y, Wu X, Chen F, Li H, Wang T, Liu N, Sun K, Zhou G, Tao K. Modulating cancer-stroma crosstalk by a nanoparticle-based photodynamic method to pave the way for subsequent therapies. Biomaterials 2022;289:121813. [PMID: 36152513 DOI: 10.1016/j.biomaterials.2022.121813] [Reference Citation Analysis]
12 Yin X, Chen Y, Ruze R, Xu R, Song J, Wang C, Xu Q. The evolving view of thermogenic fat and its implications in cancer and metabolic diseases. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-01178-6] [Reference Citation Analysis]
13 Dai M, Zhang H, Yang Y, Xiu D, Peng B, Sun B, Cao F, Wu Z, Wang L, Yuan C, Chen H, Wang Z, Tian X, Wang H, Liu W, Xu J, Liu Q, Zhao Y; MIRROR study group. The effect of minimally invasive or open radical antegrade modular pancreatosplenectomy on pancreatic cancer: A multicenter randomized clinical trial protocol. Front Oncol 2022;12:965508. [DOI: 10.3389/fonc.2022.965508] [Reference Citation Analysis]
14 He YG, Huang XB, Li YM, Li J, Peng XH, Huang W, Tang YC, Zheng L. Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study. World J Gastrointest Oncol 2022; 14(9): 1785-1797 [DOI: 10.4251/wjgo.v14.i9.1785] [Reference Citation Analysis]
15 Ma D, Yang Y, Cai Q, Ye F, Deng X, Shen B. Identification of a lncRNA based signature for pancreatic cancer survival to predict immune landscape and potential therapeutic drugs. Front Genet 2022;13:973444. [DOI: 10.3389/fgene.2022.973444] [Reference Citation Analysis]
16 Ferrara B, Dugnani E, Sordi V, Pasquale V, Pellegrini S, Reni M, Balzano G, Piemonti L. A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma. IJMS 2022;23:10663. [DOI: 10.3390/ijms231810663] [Reference Citation Analysis]
17 Xia C, Chen D, Wang G, Sun H, Lin J, Chen C, Shen T, Cheng H, Pan C, Xu D, Yang H, Zhu Y, Zhu H, Tang M. Identification of Molecular Targets and Underlying Mechanisms of Xiaoji Recipe against Pancreatic Cancer Based on Network Pharmacology. Computational and Mathematical Methods in Medicine 2022;2022:1-17. [DOI: 10.1155/2022/4640849] [Reference Citation Analysis]
18 Stanciu S, Ionita-Radu F, Stefani C, Miricescu D, Stanescu-Spinu II, Greabu M, Ripszky Totan A, Jinga M. Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects. Int J Mol Sci 2022;23:10132. [PMID: 36077529 DOI: 10.3390/ijms231710132] [Reference Citation Analysis]
19 Liu C, Qin H, Liu H, Wei T, Wu Z, Shang M, Liu H, Wang A, Liu J, Shang D, Yin P. Tissue metabolomics identified new biomarkers for the diagnosis and prognosis prediction of pancreatic cancer. Front Oncol 2022;12:991051. [DOI: 10.3389/fonc.2022.991051] [Reference Citation Analysis]
20 Yu Y, Zou YF, Hong RQ, Chen WJ, Chen L, Chen WQ, Wang HP, Yu Y. Long non-coding RNA SNHG16 decreased SMAD4 to induce gemcitabine resistance in pancreatic cancer via EZH2-mediated epigenetic modification. Kaohsiung J Med Sci 2022. [PMID: 36053032 DOI: 10.1002/kjm2.12574] [Reference Citation Analysis]
21 Fan Y, Li X, Sun H, Gao Z, Zhu Z, Yuan K. Role of WTAP in Cancer: From Mechanisms to the Therapeutic Potential. Biomolecules 2022;12:1224. [PMID: 36139062 DOI: 10.3390/biom12091224] [Reference Citation Analysis]
22 Li T, Wang Y, Zhao B, Qin C, Li Z, Wang W. Phospholipase A/acyltransferase 4 is a prognostic biomarker and correlated with immune infiltrates in pancreatic cancer. Heliyon 2022;8:e10416. [DOI: 10.1016/j.heliyon.2022.e10416] [Reference Citation Analysis]
23 Li Y, Cao L, Shen C, Meng F, Li Y, Wang S, Li Y, Li Y, Liu H, Liu Q. Heterostructure photoelectrochemical immunosensor based on flower-like refraction structure Cd-ZnIn2.2Sy sensitized 2D hexagonal SnS2 nanoplates for CA242 detection. Sensors and Actuators B: Chemical 2022;367:132186. [DOI: 10.1016/j.snb.2022.132186] [Reference Citation Analysis]
24 Bian S, Dong H, Zhao L, Li Z, Chen J, Zhu X, Qiu N, Jia X, Song W, Li Z, Zheng S, Wang H, Song P. Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer. Adv Sci (Weinh) 2022;:e2201931. [PMID: 36026578 DOI: 10.1002/advs.202201931] [Reference Citation Analysis]
25 Yang S, Zhang Y, Hua Y, Cui M, Wang M, Gao J, Liu Q, Liao Q. GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma. Front Oncol 2022;12:968610. [DOI: 10.3389/fonc.2022.968610] [Reference Citation Analysis]
26 Vera R, Ibarrola-de-Andrés C, Adeva J, Pérez-Rojas J, García-Alfonso P, Rodríguez-Gil Y, Macarulla T, Serrano-Piñol T, Mondéjar R, Madrigal-Rubiales B. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer. Clin Transl Oncol 2022. [PMID: 36008616 DOI: 10.1007/s12094-022-02873-0] [Reference Citation Analysis]
27 Ji H, Zhang Q, Wang XX, Li J, Wang X, Pan W, Zhang Z, Ma B, Zhang HM. Identification of stromal microenvironment characteristics and key molecular mining in pancreatic cancer. Discov Oncol 2022;13:83. [PMID: 36006549 DOI: 10.1007/s12672-022-00532-y] [Reference Citation Analysis]
28 Huang X, Zhou S, Tóth J, Hajdu A. Cuproptosis-related gene index: A predictor for pancreatic cancer prognosis, immunotherapy efficacy, and chemosensitivity. Front Immunol 2022;13:978865. [DOI: 10.3389/fimmu.2022.978865] [Reference Citation Analysis]
29 Ma Y, Lyu J, Yang B, Yan T, Ma Q, Wu Z, Wang Z, He H. Incidence and risk factors of suicide among patients with pancreatic cancer: A population-based analysis from 2000 to 2018. Front Oncol 2022;12:972908. [DOI: 10.3389/fonc.2022.972908] [Reference Citation Analysis]
30 Wang M, Wu M, Liu X, Shao S, Huang J, Liu B, Liang T. Pyroptosis Remodeling Tumor Microenvironment to Enhance Pancreatic Cancer Immunotherapy Driven by Membrane Anchoring Photosensitizer. Adv Sci (Weinh) 2022;:e2202914. [PMID: 35981886 DOI: 10.1002/advs.202202914] [Reference Citation Analysis]
31 Xu Y, Li Z, Shi H, Zhu M. Clinicopathological and prognostic significance of circulating immune cells in the patients with pancreatic cancer. Int Immunopharmacol 2022;111:109157. [PMID: 35988520 DOI: 10.1016/j.intimp.2022.109157] [Reference Citation Analysis]
32 Frigerio I, Malleo G, de Pastena M, Deiro G, Surci N, Scopelliti F, Esposito A, Regi P, Giardino A, Allegrini V, Bassi C, Girelli R, Salvia R, Butturini G. Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver. Ann Surg Oncol 2022. [PMID: 35976466 DOI: 10.1245/s10434-022-12385-4] [Reference Citation Analysis]
33 Takikawa T, Hamada S, Matsumoto R, Tanaka Y, Kataoka F, Sasaki A, Masamune A. Senescent Human Pancreatic Stellate Cells Secrete CXCR2 Agonist CXCLs to Promote Proliferation and Migration of Human Pancreatic Cancer AsPC-1 and MIAPaCa-2 Cell Lines. IJMS 2022;23:9275. [DOI: 10.3390/ijms23169275] [Reference Citation Analysis]
34 Feng Z, Li K, Qin K, Liang J, Shi M, Ma Y, Zhao S, Liang H, Han D, Shen B, Peng C, Chen H, Jiang L. The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. J Hematol Oncol 2022;15:112. [PMID: 35978332 DOI: 10.1186/s13045-022-01338-9] [Reference Citation Analysis]
35 Mo J, Cui Z, Wang Q, Zhang W, Li J, Wu S, Qian W, Zhou C, Ma Q, Wang Z, Wu Z. Integrated analysis of necroptosis-related lncRNAs for prognosis and immunotherapy of patients with pancreatic adenocarcinoma. Front Genet 2022;13:940794. [DOI: 10.3389/fgene.2022.940794] [Reference Citation Analysis]
36 Zhang D, Wu S, Pan S, Wang M, Wang Z, He Z, Zhang G, Cui F, Song Y, Li W, Shi X, Huang H, Xu H. Single-cell sequencing reveals heterogeneity between pancreatic adenosquamous carcinoma and pancreatic ductal adenocarcinoma with prognostic value. Front Immunol 2022;13:972298. [DOI: 10.3389/fimmu.2022.972298] [Reference Citation Analysis]
37 Braun R, Klinkhammer-schalke M, Zeissig SR, Kleihus van Tol K, Bolm L, Honselmann KC, Petrova E, Lapshyn H, Deichmann S, Abdalla TSA, Heckelmann B, Bronsert P, Zemskov S, Hummel R, Keck T, Wellner UF. Clinical Outcome and Prognostic Factors of Pancreatic Adenosquamous Carcinoma Compared to Ductal Adenocarcinoma—Results from the German Cancer Registry Group. Cancers 2022;14:3946. [DOI: 10.3390/cancers14163946] [Reference Citation Analysis]
38 Zhu Z, Chen L, Miao D, Jin Y, Wu Q. Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma. Front Genet 2022;13:941389. [DOI: 10.3389/fgene.2022.941389] [Reference Citation Analysis]
39 Gongye X, Tian M, Xia P, Qu C, Chen Z, Wang J, Zhu Q, Li Z, Yuan Y. Multi-omics analysis revealed the role of extracellular vesicles in hepatobiliary & pancreatic tumor. J Control Release 2022;350:11-25. [PMID: 35963466 DOI: 10.1016/j.jconrel.2022.08.010] [Reference Citation Analysis]
40 Li C, Wang M, Wei J, Zhang W, Liu H, Zhao D. Construction of a Pyroptosis-Related Genes Signature to Improve the Prognostic Prediction and Therapeutic Drugs Selection in Patients with Pancreatic Cancer. Int J Gen Med 2022;15:6387-403. [PMID: 35942290 DOI: 10.2147/IJGM.S369209] [Reference Citation Analysis]
41 Caban M, Małecka-wojciesko E. Pancreatic Incidentaloma. JCM 2022;11:4648. [DOI: 10.3390/jcm11164648] [Reference Citation Analysis]
42 Xue S, Ge W, Wang K, Mao T, Zhang X, Xu H, Wang Y, Yao J, Li S, Yue M, Ma J, Wang Y, Shentu D, Cui J, Wang L. Association of aging-related genes with prognosis and immune infiltration in pancreatic adenocarcinoma. Front Cell Dev Biol 2022;10:942225. [DOI: 10.3389/fcell.2022.942225] [Reference Citation Analysis]
43 Chang C, Li X, Cheng K, Cai Z, Xiong J, Lv W, Li R, Zhang P, Cao D. A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. Oncologist 2022:oyac146. [PMID: 35930304 DOI: 10.1093/oncolo/oyac146] [Reference Citation Analysis]
44 Xu D, Tian M, Chen W, Bian Y, Xia X, Liu Q, Zheng L, Zhang X, Shen H, Pandurangan A. Linderalactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signaling Pathway. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/8675096] [Reference Citation Analysis]
45 Peng B, Chen G, Li Y, Zhang H, Shen J, Hou JT, Li Z. NQO-1 Enzyme-Activated NIR Theranostic Agent for Pancreatic Cancer. Anal Chem 2022. [PMID: 35916489 DOI: 10.1021/acs.analchem.2c01189] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Seelen LWF, van den Wildenberg L, van der Kemp WJM, Mohamed Hoesein FAA, Mohammad NH, Molenaar IQ, van Santvoort HC, Prompers JJ, Klomp DWJ. Prospective of 31 P MR Spectroscopy in Hepatopancreatobiliary Cancer: A Systematic Review of the Literature. J Magn Reson Imaging 2022. [PMID: 35916278 DOI: 10.1002/jmri.28372] [Reference Citation Analysis]
47 Shi SY, Wang L, Peng Z, Wang Y, Lin Z, Hu X, Yuan J, Huang L, Feng ST, Luo Y. Multi-frequency magnetic resonance elastography of the pancreas: measurement reproducibility and variance among healthy volunteers. Gastroenterol Rep (Oxf) 2022;10:goac033. [PMID: 35910246 DOI: 10.1093/gastro/goac033] [Reference Citation Analysis]
48 Sargazi S, Laraib U, Barani M, Rahdar A, Fatima I, Bilal M, Pandey S, Sharma RK, Kyzas GZ. Recent trends in mesoporous silica nanoparticles of rode-like morphology for cancer theranostics: A review. Journal of Molecular Structure 2022;1261:132922. [DOI: 10.1016/j.molstruc.2022.132922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Hwang WL, Jagadeesh KA, Guo JA, Hoffman HI, Yadollahpour P, Reeves JW, Mohan R, Drokhlyansky E, Van Wittenberghe N, Ashenberg O, Farhi SL, Schapiro D, Divakar P, Miller E, Zollinger DR, Eng G, Schenkel JM, Su J, Shiau C, Yu P, Freed-Pastor WA, Abbondanza D, Mehta A, Gould J, Lambden C, Porter CBM, Tsankov A, Dionne D, Waldman J, Cuoco MS, Nguyen L, Delorey T, Phillips D, Barth JL, Kem M, Rodrigues C, Ciprani D, Roldan J, Zelga P, Jorgji V, Chen JH, Ely Z, Zhao D, Fuhrman K, Fropf R, Beechem JM, Loeffler JS, Ryan DP, Weekes CD, Ferrone CR, Qadan M, Aryee MJ, Jain RK, Neuberg DS, Wo JY, Hong TS, Xavier R, Aguirre AJ, Rozenblatt-Rosen O, Mino-Kenudson M, Castillo CF, Liss AS, Ting DT, Jacks T, Regev A. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Nat Genet 2022. [PMID: 35902743 DOI: 10.1038/s41588-022-01134-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
50 Wietrzykowska-Grishanovich D, Pawlik E, Neubauer K. Biochemical Intracystic Biomarkers in the Differential Diagnosis of Pancreatic Cystic Lesions. Medicina (Kaunas) 2022;58:994. [PMID: 35893110 DOI: 10.3390/medicina58080994] [Reference Citation Analysis]
51 Husain K, Villalobos-Ayala K, Laverde V, Vazquez OA, Miller B, Kazim S, Blanck G, Hibbs ML, Krystal G, Elhussin I, Mori J, Yates C, Ghansah T. Apigenin Targets MicroRNA-155, Enhances SHIP-1 Expression, and Augments Anti-Tumor Responses in Pancreatic Cancer. Cancers (Basel) 2022;14:3613. [PMID: 35892872 DOI: 10.3390/cancers14153613] [Reference Citation Analysis]
52 Kirkegård J, Bojesen AB, Nielsen MF, Mortensen FV. Trends in pancreatic cancer incidence, characteristics, and outcomes in Denmark 1980-2019: A nationwide cohort study. Cancer Epidemiol 2022;80:102230. [PMID: 35901622 DOI: 10.1016/j.canep.2022.102230] [Reference Citation Analysis]
53 Terashima T, Morizane C, Ushiama M, Shiba S, Takahashi H, Ikeda M, Mizuno N, Tsuji K, Yasui K, Azemoto N, Satake H, Nomura S, Yachida S, Sugano K, Furuse J. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. Jpn J Clin Oncol 2022:hyac110. [PMID: 36135357 DOI: 10.1093/jjco/hyac110] [Reference Citation Analysis]
54 Zhang Y, Xu Y, Lu W, Li J, Yu S, Brown EJ, Stanger BZ, Rabinowitz JD, Yang X. G6PD-mediated increase in de novo NADP+ biosynthesis promotes antioxidant defense and tumor metastasis. Sci Adv 2022;8:eabo0404. [PMID: 35857842 DOI: 10.1126/sciadv.abo0404] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Hu X, Lei X, Guo J, Fu W, Sun W, Lu Q, Su W, Xu Q, Tu K. The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer. Front Oncol 2022;12:927640. [DOI: 10.3389/fonc.2022.927640] [Reference Citation Analysis]
56 Smith C, Zheng W, Dong J, Wang Y, Lai J, Liu X, Yin F. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy. World J Gastroenterol 2022; 28(27): 3297-3313 [DOI: 10.3748/wjg.v28.i27.3297] [Reference Citation Analysis]
57 Vay C, Babaei S, Safi S, Dizdar L, Rehders A, Haeberle L, Roderburg C, Loosen SH, Esposito I, Knoefel WT, Krieg A. Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma. Cancers 2022;14:3494. [DOI: 10.3390/cancers14143494] [Reference Citation Analysis]
58 Fujiwara-Tani R, Sasaki T, Takagi T, Mori S, Kishi S, Nishiguchi Y, Ohmori H, Fujii K, Kuniyasu H. Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism. Int J Mol Sci 2022;23:7824. [PMID: 35887170 DOI: 10.3390/ijms23147824] [Reference Citation Analysis]
59 Gkountakos A, Mafficini A, Lou E, Malleo G, Salvia R, Calicchia M, Silvestris N, Racila E, Amin K, Veronese N, Brunetti O, Antonini P, Ingravallo G, Mattiolo P, Saponaro C, Nappo F, Simbolo M, Bariani E, Lonardi S, Fassan M, Milella M, Lawlor RT, Scarpa A, Luchini C. Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas. Hum Pathol 2022:S0046-8177(22)00184-8. [PMID: 35850360 DOI: 10.1016/j.humpath.2022.07.011] [Reference Citation Analysis]
60 Sheel A, Addison S, Nuguru SP, Manne A. Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time? Cancers (Basel) 2022;14:3453. [PMID: 35884515 DOI: 10.3390/cancers14143453] [Reference Citation Analysis]
61 Zhang W, Zhan J, Zhao R, Xu Y, Zeng Y, Xiao Q, Ye W, Wu Y, Cai Y, Fang C. Parallelism to Conquer: Binary Supramolecular Peptide Amphiphiles Launch Synergistic Stromal Reprogramming to Remove the Baffle in Pancreatic Cancer Therapy. Adv Funct Materials. [DOI: 10.1002/adfm.202203767] [Reference Citation Analysis]
62 Cai J, Chen H, Lu M, Zhang Y, Lu B, Luo C, Feng X, You L, Dai M, Zhao Y. Association between Temporal Glycemic Change and Risk of Pancreatic Cancer in Men: A Prospective Cohort Study. Cancers 2022;14:3403. [DOI: 10.3390/cancers14143403] [Reference Citation Analysis]
63 He R, Yin T, Pan S, Wang M, Zhang H, Qin R. One hundred most cited article related to pancreaticoduodenectomy surgery: A bibliometric analysis. Int J Surg 2022;:106775. [PMID: 35840048 DOI: 10.1016/j.ijsu.2022.106775] [Reference Citation Analysis]
64 Ma Y, Di Y, Li Q, Zhan Q, He X, Liu S, Zou H, Corpe C, Chen L, Wang J. LncRNAs as epigenetic regulators of epithelial to mesenchymal transition in pancreatic cancer. Discov Oncol 2022;13:61. [PMID: 35819532 DOI: 10.1007/s12672-022-00522-0] [Reference Citation Analysis]
65 Butnariu M, Quispe C, Herrera-Bravo J, Helon P, Kukula-Koch W, López V, Les F, Vergara CV, Alarcón-Zapata P, Alarcón-Zapata B, Martorell M, Pentea M, Dragunescu AA, Samfira I, Yessimsiitova Z, Daştan SD, Castillo CMS, Roberts TH, Sharifi-Rad J, Koch W, Cho WC. The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies. Biomed Pharmacother 2022;153:113364. [PMID: 35810693 DOI: 10.1016/j.biopha.2022.113364] [Reference Citation Analysis]
66 Yang JM, Yang XY, Wan JH. Multiple roles for cholinergic signaling in pancreatic diseases. World J Gastroenterol 2022; 28(25): 2910-2919 [DOI: 10.3748/wjg.v28.i25.2910] [Reference Citation Analysis]
67 Zhao K, Li X, Shi Y, Lu Y, Qiu P, Deng Z, Yao W, Wang J. A Comprehensive Analysis of Pyroptosis-Related lncRNAs Signature Associated With Prognosis and Tumor Immune Microenvironment of Pancreatic Adenocarcinoma. Front Genet 2022;13:899496. [DOI: 10.3389/fgene.2022.899496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Zhang P, Xiao Z, Xu H, Zhu X, Wang L, Huang D, Liang Y, Ni Q, Chen J, Yu X, Luo G. Hyperglycemia is associated with adverse prognosis in patients with pancreatic neuroendocrine neoplasms. Endocrine 2022. [PMID: 35790660 DOI: 10.1007/s12020-022-03100-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Masugi Y. The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities. Cancers 2022;14:3293. [DOI: 10.3390/cancers14133293] [Reference Citation Analysis]
70 Lindgaard SC, Maag E, Sztupinszki Z, Chen IM, Johansen AZ, Jensen BV, Bojesen SE, Nielsen DL, Szallasi Z, Johansen JS. Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy. Cancers 2022;14:3250. [DOI: 10.3390/cancers14133250] [Reference Citation Analysis]
71 Mohammadzadeh V, Rahiman N, Hosseinikhah SM, Barani M, Rahdar A, Jaafari MR, Sargazi S, Zirak MR, Pandey S, Bhattacharjee R, Gupta AK, Thakur VK, Sibuh BZ, Gupta PK. Novel EPR-enhanced strategies for targeted drug delivery in pancreatic cancer: An update. Journal of Drug Delivery Science and Technology 2022;73:103459. [DOI: 10.1016/j.jddst.2022.103459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Jin X, Dong C, Zheng K, Shi X, Liu Y, Huo L, Wang F, Li F. Scintigraphic Imaging of Neovascularization With 99mTc-3PRGD2 for Evaluating Early Response to Endostar Involved Therapies on Pancreatic Cancer Xenografts In Vivo. Front Oncol 2021;11:792431. [PMID: 35769548 DOI: 10.3389/fonc.2021.792431] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
73 Zhao W, Yang S, Li C, Li F, Pang H, Xu G, Wang Y, Cong M. Amphiphilic Dendritic Nanomicelle-Mediated Delivery of Gemcitabine for Enhancing the Specificity and Effectiveness. IJN 2022;Volume 17:3239-49. [DOI: 10.2147/ijn.s371775] [Reference Citation Analysis]
74 Ding C, Yu Z, Zhu J, Li X, Dai M, QiangHe. Construction and Validation of a Necroptosis-Related Gene Signature for Predicting Prognosis and Tumor Microenvironment of Pancreatic Cancer. Dis Markers 2022;2022:9737587. [PMID: 35756487 DOI: 10.1155/2022/9737587] [Reference Citation Analysis]
75 Xie F, Huang X, He C, Wang R, Li S. An Inflammatory Response-Related Gene Signature Reveals Distinct Survival Outcome and Tumor Microenvironment Characterization in Pancreatic Cancer. Front Mol Biosci 2022;9:876607. [PMID: 35755810 DOI: 10.3389/fmolb.2022.876607] [Reference Citation Analysis]
76 Ge W, Ma J, Mao T, Xu H, Zhang X, Li S, Wang Y, Yao J, Yue M, Jiao F, Wang Y, Zhuo M, Han T, Hu J, Zhang X, Cui J, Wang L. Distinguishable Prognostic Signatures and Tumor Immunogenicity Between Pancreatic Head Cancer and Pancreatic Body/Tail Cancer. Front Oncol 2022;12:890715. [PMID: 35756644 DOI: 10.3389/fonc.2022.890715] [Reference Citation Analysis]
77 Li B, Feng Y, Hou Q, Fu Y, Luo Y. Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers. IJMS 2022;23:7168. [DOI: 10.3390/ijms23137168] [Reference Citation Analysis]
78 Xia Z, Kong F, Wang K, Zhang X. Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours. Front Pharmacol 2022;13:908079. [PMID: 35754499 DOI: 10.3389/fphar.2022.908079] [Reference Citation Analysis]
79 Yu W, Tu Y, Long Z, Liu J, Kong D, Peng J, Wu H, Zheng G, Zhao J, Chen Y, Liu R, Li W, Hai C, Zhou J. Reactive Oxygen Species Bridge the Gap between Chronic Inflammation and Tumor Development. Oxidative Medicine and Cellular Longevity 2022;2022:1-22. [DOI: 10.1155/2022/2606928] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Ji D, Hou L, Xie C, Feng H, Bao D, Teng Y, Liu J, Cui T, Wang X, Xu Y, Tan G, Ding X. Deoxyelephantopin Suppresses Pancreatic Cancer Progression In Vitro and In Vivo by Targeting linc00511/miR-370-5p/p21 Promoter Axis. Journal of Oncology 2022;2022:1-19. [DOI: 10.1155/2022/3855462] [Reference Citation Analysis]
81 Huang CJ, Huang WY, Chen CY, Chao YJ, Chiang NJ, Shan YS. Cancer-cell-derived cell-free DNA can predict distant metastasis earlier in pancreatic cancer: a prospective cohort study. Ther Adv Med Oncol 2022;14:17588359221106558. [PMID: 35747164 DOI: 10.1177/17588359221106558] [Reference Citation Analysis]
82 Diego-gonzález L, Fernández-carrera A, Igea A, Martínez-pérez A, Real Oliveira MECD, Gomes AC, Guerra C, Barbacid M, González-fernández Á, Simón-vázquez R. Combined Inhibition of FOSL-1 and YAP Using siRNA-Lipoplexes Reduces the Growth of Pancreatic Tumor. Cancers 2022;14:3102. [DOI: 10.3390/cancers14133102] [Reference Citation Analysis]
83 You W, Ke J, Chen Y, Cai Z, Huang ZP, Hu P, Wu X. SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma. Front Immunol 2022;13:864244. [PMID: 35720314 DOI: 10.3389/fimmu.2022.864244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Chen Q, Li J, Shen P, Yuan H, Yin J, Ge W, Wang W, Chen G, Yang T, Xiao B, Miao Y, Lu Z, Wu P, Jiang K. Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star. Cell Biosci 2022;12:97. [PMID: 35729650 DOI: 10.1186/s13578-022-00833-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
85 Garcia PL, Miller AL, Zeng L, van Waardenburg RCAM, Yang ES, Yoon KJ. The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells. Front Oncol 2022;12:925718. [DOI: 10.3389/fonc.2022.925718] [Reference Citation Analysis]
86 Li K, Xiao Y, Bian J, Han L, He C, El-Omar E, Gong L, Wang M. Ameliorative Effects of Gut Microbial Metabolite Urolithin A on Pancreatic Diseases. Nutrients 2022;14:2549. [PMID: 35745279 DOI: 10.3390/nu14122549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Xu ZH, Wang WQ, Liu L, Lou WH. A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer. Biochim Biophys Acta Rev Cancer 2022;1877:188751. [PMID: 35732240 DOI: 10.1016/j.bbcan.2022.188751] [Reference Citation Analysis]
88 Mortazavi M, Moosavi F, Martini M, Giovannetti E, Firuzi O. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Crit Rev Oncol Hematol 2022;:103749. [PMID: 35728737 DOI: 10.1016/j.critrevonc.2022.103749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
89 Tian W, Hao H, Chu M, Gong J, Li W, Fang Y, Zhang J, Zhang C, Huang Y, Pei F, Duan L. Berberine Suppresses Lung Metastasis of Cancer via Inhibiting Endothelial Transforming Growth Factor Beta Receptor 1. Front Pharmacol 2022;13:917827. [DOI: 10.3389/fphar.2022.917827] [Reference Citation Analysis]
90 Zhou Y, Li X, Luo W, Zhu J, Zhao J, Wang M, Sang L, Chang B, Wang B. Allicin in Digestive System Cancer: From Biological Effects to Clinical Treatment. Front Pharmacol 2022;13:903259. [DOI: 10.3389/fphar.2022.903259] [Reference Citation Analysis]
91 Wang L, Liu Y, Dai Y, Tang X, Yin T, Wang C, Wang T, Dong L, Shi M, Qin J, Xue M, Cao Y, Liu J, Liu P, Huang J, Wen C, Zhang J, Xu Z, Bai F, Deng X, Peng C, Chen H, Jiang L, Chen S, Shen B. Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment. Gut 2022:gutjnl-2021-326070. [PMID: 35688610 DOI: 10.1136/gutjnl-2021-326070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
92 Wang X, Zeng H, Zhu X, Xu D, Tian Q, Wang C, Zhao L, Zhao J, Miao M, Wu X. TP-CSO: A Triptolide Prodrug for Pancreatic Cancer Treatment. Molecules 2022;27:3686. [PMID: 35744811 DOI: 10.3390/molecules27123686] [Reference Citation Analysis]
93 Yu S, Li Z, Tu L, Pu Y, Yan D, Wang X, Zheng X, Yu J. Uricase sensitizes hepatocellular carcinoma cells to 5-fluorouracil through uricase-uric acid-UMP synthase axis. J Physiol Biochem 2022. [PMID: 35674867 DOI: 10.1007/s13105-022-00894-5] [Reference Citation Analysis]
94 Pruitt SL, Tavakkoli A, Zhu H, Heitjan DF, Gerber DE, Singal AG, Halm EA, Beg MS, Maddineni B, Kansagra AJ, Murphy CC. Survival of cancer survivors with a new pancreatic cancer diagnosis. Cancer Med 2022. [PMID: 35674139 DOI: 10.1002/cam4.4903] [Reference Citation Analysis]
95 Fei X, Kong L, Shi C, Wang G, Liu C, Wang C, Liu P, Tan X, Bu D. Identification of Prognosis-Related Molecular Subgroups and Construction of a Prognostic Prediction Model Using Immune-Related Genes in Pancreatic Cancer. Journal of Oncology 2022;2022:1-21. [DOI: 10.1155/2022/7117014] [Reference Citation Analysis]
96 Voisin T, Nicole P, Gratio V, Chassac A, Mansour D, Rebours V, Couvelard A, Couvineau A. The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment. Front Oncol 2022;12:904327. [DOI: 10.3389/fonc.2022.904327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Murakami T, Matsui Y. Laparoscopic duodenojejunostomy for malignant stenosis as a part of multimodal therapy: A case report. World J Clin Cases 2022; 10(16): 5324-5330 [DOI: 10.12998/wjcc.v10.i16.5324] [Reference Citation Analysis]
98 Wu X, Yu R, Yang M, Hu Y, Tang M, Zhang S, Abudourousuli A, Li X, Li Z, Liao X, Xu Y, Li M, Chen S, Qian W, Feng R, Li J, Li F. Integrated Analysis of Glutathione Metabolic Pathway in Pancreatic Cancer. Front Cell Dev Biol 2022;10:896136. [DOI: 10.3389/fcell.2022.896136] [Reference Citation Analysis]
99 Arechederra M, Rullán M, Amat I, Oyon D, Zabalza L, Elizalde M, Latasa MU, Mercado MR, Ruiz-Clavijo D, Saldaña C, Fernández-Urién I, Carrascosa J, Jusué V, Guerrero-Setas D, Zazpe C, González-Borja I, Sangro B, Herranz JM, Purroy A, Gil I, Nelson LJ, Vila JJ, Krawczyk M, Zieniewicz K, Patkowski W, Milkiewicz P, Cubero FJ, Alkorta-Aranburu G, G Fernandez-Barrena M, Urman JM, Berasain C, Avila MA. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut 2022;71:1141-51. [PMID: 34285068 DOI: 10.1136/gutjnl-2021-325178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
100 Wu C, Liu Y, Wei D, Tao L, Yuan L, Jing T, Wang B. Gene Coexpression Network Characterizing Microenvironmental Heterogeneity and Intercellular Communication in Pancreatic Ductal Adenocarcinoma: Implications of Prognostic Significance and Therapeutic Target. Front Oncol 2022;12:840474. [DOI: 10.3389/fonc.2022.840474] [Reference Citation Analysis]
101 Hyung J, Lee H, Jin H, Lee S, Lee H, Gong G, Song T, Lee S, Hwang D, Kim S, Jeong J, Ryoo B, Kim K, Yoo C. Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX. ESMO Open 2022;7:100484. [DOI: 10.1016/j.esmoop.2022.100484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Li L, Deng Z, Xiao Z, Zou W, Liu R. Analysis of Pyroptosis-Related Signature for Predicting Prognosis and Tumor Immune Microenvironment in Pancreatic Cancer. Front Oncol 2022;12:770005. [DOI: 10.3389/fonc.2022.770005] [Reference Citation Analysis]
103 Olson MT, Aguilar EN, Brooks CL, Isder CC, Muilenburg KM, Talmon GA, Ly QP, Carlson MA, Hollingsworth MA, Mohs AM. Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic Cancer. Mol Pharm 2022. [PMID: 35640060 DOI: 10.1021/acs.molpharmaceut.2c00203] [Reference Citation Analysis]
104 Shinoda S, Nakamura N, Roach B, Bernlohr DA, Ikramuddin S, Yamamoto M. Obesity and Pancreatic Cancer: Recent Progress in Epidemiology, Mechanisms and Bariatric Surgery. Biomedicines 2022;10:1284. [DOI: 10.3390/biomedicines10061284] [Reference Citation Analysis]
105 Xie W, Li X, Yang C, Li J, Shen G, Chen H, Xiao SY, Li Y. The Pyroptosis-Related Gene Prognostic Index Associated with Tumor Immune Infiltration for Pancreatic Cancer. Int J Mol Sci 2022;23:6178. [PMID: 35682857 DOI: 10.3390/ijms23116178] [Reference Citation Analysis]
106 Okuno M, Mukai T, Iwata K, Watanabe N, Tanaka T, Iwasa T, Shimojo K, Ohashi Y, Takagi A, Ito Y, Tezuka R, Iwata S, Iwasa Y, Kochi T, Ogiso T, Hayashi H, Sugiyama A, Nishigaki Y, Tomita E. Evaluation of the Cell Block Method Using Overnight-Stored Bile for Malignant Biliary Stricture Diagnosis. Cancers (Basel) 2022;14:2701. [PMID: 35681681 DOI: 10.3390/cancers14112701] [Reference Citation Analysis]
107 Xu Y, Xiong Q, Yang Y, Weng N, Li J, Liu J, Yang X, Zeng Z, Zhang Z, Zhu Q. Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. JCM 2022;11:3101. [DOI: 10.3390/jcm11113101] [Reference Citation Analysis]
108 Lai H, Kuo Y, Huang Y, Chan S, Cheng K, Wu Z. Pancreatic Cancer and Microenvironments: Implications of Anesthesia. Cancers 2022;14:2684. [DOI: 10.3390/cancers14112684] [Reference Citation Analysis]
109 Kamal MA, Siddiqui I, Belgiovine C, Barbagallo M, Paleari V, Pistillo D, Chiabrando C, Schiarea S, Bottazzi B, Leone R, Avigni R, Migliore R, Spaggiari P, Gavazzi F, Capretti G, Marchesi F, Mantovani A, Zerbi A, Allavena P. Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer. Cancers 2022;14:2653. [DOI: 10.3390/cancers14112653] [Reference Citation Analysis]
110 Han X, Zhang WH, Gao HL, Li TJ, Xu HX, Li H, Li PC, Wang X, Yu XJ, Wang WQ, Liu L. Neoadjuvant chemotherapy endows CD9 with prognostic value that differs between tumor and stromal areas in patients with pancreatic cancer. J Clin Lab Anal 2022;:e24517. [PMID: 35622458 DOI: 10.1002/jcla.24517] [Reference Citation Analysis]
111 Chan CY, Chen Z, Destro G, Veal M, Lau D, O'Neill E, Dias G, Mosley M, Kersemans V, Guibbal F, Gouverneur V, Cornelissen B. Imaging PARP with [18F]rucaparib in pancreatic cancer models. Eur J Nucl Med Mol Imaging 2022. [PMID: 35614267 DOI: 10.1007/s00259-022-05835-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
112 Gu X, Zhu Q, Tian G, Song W, Wang T, Wang A, Chen X, Qin S. KIF11 manipulates SREBP2-dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinoma. Cancer Med 2022. [PMID: 35619540 DOI: 10.1002/cam4.4683] [Reference Citation Analysis]
113 Zhou S, Yu Z, Shi X, Zhao H, Dai M, Chen W. The Relationship between Phase Angle, Nutrition Status, and Complications in Patients with Pancreatic Head Cancer. IJERPH 2022;19:6426. [DOI: 10.3390/ijerph19116426] [Reference Citation Analysis]
114 Servetto A, Santaniello A, Napolitano F, Foschini F, Marciano R, Cascetta P, Amato AR, Augurio MR, Maresca L, De Placido P, De Placido S, Formisano L, Bianco R. FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. Future Oncol 2022. [PMID: 35608115 DOI: 10.2217/fon-2021-1142] [Reference Citation Analysis]
115 Lin X, Xiao M, Chen Z, Ding C, Zhang T, Li Q, Xu Y. Pancancer Analyses Reveal Genomics and Clinical Characteristics of the SETDB1 in Human Tumors. Journal of Oncology 2022;2022:1-40. [DOI: 10.1155/2022/6115878] [Reference Citation Analysis]
116 Kumela AG, Gemta AB, Desta TA, Kebede A. Noble classical and quantum approach to model the optical properties of metallic nanoparticles to enhance the sensitivity of optoplasmonic sensors. RSC Adv 2022;12:16203-14. [PMID: 35755132 DOI: 10.1039/d2ra00824f] [Reference Citation Analysis]
117 Choi S, Kim S, Park J, Lee SE, Kim C, Kang D. Diclofenac: A Nonsteroidal Anti-Inflammatory Drug Inducing Cancer Cell Death by Inhibiting Microtubule Polymerization and Autophagy Flux. Antioxidants 2022;11:1009. [DOI: 10.3390/antiox11051009] [Reference Citation Analysis]
118 Pietri E, Balsano R, Coriano M, Gelsomino F, Leonardi F, Bui S, Gnetti L, Valle RD, Garajová I. The implication of liquid biopsies to predict chemoresistance in pancreatic cancer. Cancer Drug Resist 2021;4:559-72. [PMID: 35582309 DOI: 10.20517/cdr.2021.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Kong L, Du J, Gu J, Deng J, Guo Y, Tao B, Jin C, Fu D, Li J. Gemcitabine-Loaded Albumin Nanoparticle Exerts An Antitumor Effect on Gemcitabine-Resistant Pancreatic Cancer Cells Induced by MDR1 and MRP1 Overexpression in Vitro. Front Surg 2022;9:890412. [DOI: 10.3389/fsurg.2022.890412] [Reference Citation Analysis]
120 Hatashima A, Arango MJ, Reardon J, Freeman T, Williams T, McLaughlin EM, Abushahin L. First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population. Future Oncol 2022. [PMID: 35579260 DOI: 10.2217/fon-2021-1367] [Reference Citation Analysis]
121 Yin MY, Xi LT, Liu L, Zhu JZ, Qian LJ, Xu CF. Pancreatic cancer incidence and mortality patterns in 2006-2015 and prediction of the epidemiological trend to 2025 in China. World J Clin Cases 2022; 10(14): 4404-4413 [DOI: 10.12998/wjcc.v10.i14.4404] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Zhang Q, Sun S, Xie Q, Wang X, Qian J, Yao J, Li Z. FAM81A identified as a stemness-related gene by screening DNA methylation sites based on machine learning-accessed stemness in pancreatic cancer. Epigenomics 2022. [PMID: 35574683 DOI: 10.2217/epi-2022-0098] [Reference Citation Analysis]
123 Du Y, Gu Z, Li Z, Yuan Z, Zhao Y, Zheng X, Bo X, Chen H, Wang C. Dynamic Interplay between Structural Variations and 3D Genome Organization in Pancreatic Cancer. Adv Sci (Weinh) 2022;:e2200818. [PMID: 35570408 DOI: 10.1002/advs.202200818] [Reference Citation Analysis]
124 Shi Y, Han Q, Yan H, Lv Y, Yuan J, Li J, Guan S, Wang Z, Huang L, Dai G. S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study. Front Oncol 2022;12:865404. [DOI: 10.3389/fonc.2022.865404] [Reference Citation Analysis]
125 Sally Á, Mcgowan R, Finn K, Moran BM. Current and Future Therapies for Pancreatic Ductal Adenocarcinoma. Cancers 2022;14:2417. [DOI: 10.3390/cancers14102417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Raza SS, Nutu OA, Powell-Brett S, Carvalheiro Boteon A, Hodson J, Abradelo M, Dasari B, Isaac J, Chatzizacharias N, Marudanayagam R, Mirza DF, Roberts JK, Sutcliffe RP. Impact of an enhanced recovery after surgery protocol on short-term outcomes in elderly patients undergoing pancreaticoduodenectomy. HPB (Oxford) 2022:S1365-182X(22)00137-X. [PMID: 35643908 DOI: 10.1016/j.hpb.2022.05.002] [Reference Citation Analysis]
127 Liu Y, Shi M, He X, Cao Y, Liu P, Li F, Zou S, Wen C, Zhan Q, Xu Z, Wang J, Sun B, Shen B. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. J Hematol Oncol 2022;15:52. [PMID: 35526050 DOI: 10.1186/s13045-022-01272-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
128 Stott MC, Oldfield L, Hale J, Costello E, Halloran CM. Recent advances in understanding pancreatic cancer. Fac Rev 2022;11:9. [PMID: 35509672 DOI: 10.12703/r/11-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
129 Li Y, Li Y, Luo J, Fu X, Liu P, Liu S, Pan Y. FAM126A interacted with ENO1 mediates proliferation and metastasis in pancreatic cancer via PI3K/AKT signaling pathway. Cell Death Discov 2022;8:248. [PMID: 35513377 DOI: 10.1038/s41420-022-01047-9] [Reference Citation Analysis]
130 Ahmadian E, Janas D, Eftekhari A, Zare N. Application of carbon nanotubes in sensing/monitoring of pancreas and liver cancer. Chemosphere 2022;302:134826. [PMID: 35525455 DOI: 10.1016/j.chemosphere.2022.134826] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
131 Huo T, Zhang X, Qian M, Nie H, Liang D, Lin C, Yang Y, Guo W, Lächelt U, Huang R. A Space-Time Conversion Vehicle for Programmed Multi-Drugs Delivery into Pancreatic Tumor to Overcome Matrix and Reflux Barriers. Adv Sci (Weinh) 2022;:e2200608. [PMID: 35508899 DOI: 10.1002/advs.202200608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Xiang Y, Dai S, Li D, Zhu X, Su J, Chen B, Wu M. Brusatol inhibits the invasion and migration of pancreatic cancer cells by suppressing the NRF2/NF-κB/STAT3 signal cascade. Journal of Functional Foods 2022;92:105024. [DOI: 10.1016/j.jff.2022.105024] [Reference Citation Analysis]
133 Schneider M, Labgaa I, Vrochides D, Zerbi A, Nappo G, Perinel J, Adham M, van Roessel S, Besselink M, Mieog JSD, Groen JV, Demartines N, Schäfer M, Joliat G. External validation of three lymph node ratio-based nomograms predicting survival using an international cohort of patients with resected pancreatic head ductal adenocarcinoma. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
134 Dutta M, Das B, Mohapatra D, Behera P, Senapati S, Roychowdhury A. MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2. Life Sci 2022;301:120592. [PMID: 35504332 DOI: 10.1016/j.lfs.2022.120592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
135 Huo Y, Yang J, Zheng J, Xu D, Yang M, Tao L, Yao H, Fu X, Yang J, Liu D, Hua R, Zhang J, Sun Y, Hu L, Liu W. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Cell Prolif 2022;:e13237. [PMID: 35487760 DOI: 10.1111/cpr.13237] [Reference Citation Analysis]
136 Deng J, Zhang Q, Lv L, Ma P, Zhang Y, Zhao N, Zhang Y. Identification of an autophagy-related gene signature for predicting prognosis and immune activity in pancreatic adenocarcinoma. Sci Rep 2022;12:7006. [PMID: 35488119 DOI: 10.1038/s41598-022-11050-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
137 Zhang Y, Zhang J, Sun P. Concerns Remain Regarding the Association of Sitting Time and Physical Activity With Cancer Survivorship. JAMA Oncol 2022. [PMID: 35482360 DOI: 10.1001/jamaoncol.2022.0868] [Reference Citation Analysis]
138 Nakayama F, Miyoshi M, Kimoto A, Kawano A, Miyashita K, Kamoshida S, Shimizu K, Hori Y. Pancreatic cancer cell-derived exosomes induce epithelial-mesenchymal transition in human pancreatic cancer cells themselves partially via transforming growth factor β1. Med Mol Morphol 2022. [PMID: 35475918 DOI: 10.1007/s00795-022-00321-0] [Reference Citation Analysis]
139 Andersson R, Haglund C, Seppänen H, Ansari D. Pancreatic cancer - the past, the present, and the future. Scand J Gastroenterol 2022;:1-9. [PMID: 35477331 DOI: 10.1080/00365521.2022.2067786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
140 Hernandez D, Wagner F, Hernandez-Villafuerte K, Schlander M. Economic Burden of Pancreatic Cancer in Europe: a Literature Review. J Gastrointest Cancer 2022. [PMID: 35474568 DOI: 10.1007/s12029-022-00821-3] [Reference Citation Analysis]
141 Jing Y, Wang F, Zhang K, Chen Z. Comprehensive analysis of prognostic value and immune infiltration of CXC chemokines in pancreatic cancer. BMC Med Genomics 2022;15:96. [PMID: 35468838 DOI: 10.1186/s12920-022-01246-4] [Reference Citation Analysis]
142 Meng Y, Yu J, Zhu M, Zhou J, Li N, Liu F, Zhang H, Fang X, Li J, Feng X, Wang L, Jiang H, Lu J, Shao C, Bian Y. CT radiomics signature: a potential biomarker for fibroblast activation protein expression in patients with pancreatic ductal adenocarcinoma. Abdom Radiol (NY) 2022. [PMID: 35451626 DOI: 10.1007/s00261-022-03512-6] [Reference Citation Analysis]
143 Beetz NL, Geisel D, Maier C, Auer TA, Shnayien S, Malinka T, Neumann CCM, Pelzer U, Fehrenbach U. Influence of Baseline CT Body Composition Parameters on Survival in Patients with Pancreatic Adenocarcinoma. JCM 2022;11:2356. [DOI: 10.3390/jcm11092356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Hong L, Xu L, Jin L, Xu K, Tang W, Zhu Y, Qiu X, Wang J. Exosomal circular RNA hsa_circ_0006220, and hsa_circ_0001666 as biomarkers in the diagnosis of pancreatic cancer. J Clin Lab Anal 2022;:e24447. [PMID: 35446993 DOI: 10.1002/jcla.24447] [Reference Citation Analysis]
145 Park BK, Seo JH, Chung JB, Choi JK. Lifestyle, body mass index, diabetes, and the risk of pancreatic cancer in a nationwide population-based cohort study with 7.4 million Korean subjects. Br J Cancer 2022. [PMID: 35444288 DOI: 10.1038/s41416-022-01807-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
146 Wang R, Guo Y, Ma P, Song Y, Min J, Zhao T, Hua L, Zhang C, Yang C, Shi J, Zhu L, Gan D, Li S, Li J, Su H. Comprehensive Analysis of 5-Methylcytosine (m5C) Regulators and the Immune Microenvironment in Pancreatic Adenocarcinoma to Aid Immunotherapy. Front Oncol 2022;12:851766. [PMID: 35433474 DOI: 10.3389/fonc.2022.851766] [Reference Citation Analysis]
147 Chen L, Jia L, Tian Z, Yang Y, Zhao K, Akhtar MF. Elderly Patients with Nondistant Metastatic Pancreatic Head Adenocarcinoma Cannot Benefit from More Radical Surgery. International Journal of Endocrinology 2022;2022:1-11. [DOI: 10.1155/2022/6469740] [Reference Citation Analysis]
148 Li W, Li T, Sun C, Du Y, Chen L, Du C, Shi J, Wang W. Identification and prognostic analysis of biomarkers to predict the progression of pancreatic cancer patients. Mol Med 2022;28. [DOI: 10.1186/s10020-022-00467-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
149 Li Y, Wang J, Wang H, Zhang S, Wei Y, Liu S. The Interplay Between Inflammation and Stromal Components in Pancreatic Cancer. Front Immunol 2022;13:850093. [DOI: 10.3389/fimmu.2022.850093] [Reference Citation Analysis]
150 Tan Z, Shi S, Xu J, Liu X, Lei Y, Zhang B, Hua J, Meng Q, Wang W, Yu X, Liang C. RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner. Oncogene. [DOI: 10.1038/s41388-022-02306-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
151 de la Fouchardière C, Gamradt P, Chabaud S, Raddaz M, Blanc E, Msika O, Treilleux I, Bachy S, Cattey-javouhey A, Guibert P, Sarabi M, Rochefort P, Funk-debleds P, Coutzac C, Ray-coquard I, Peyrat P, Meeus P, Rivoire M, Dupré A, Hennino A. A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3. JPM 2022;12:623. [DOI: 10.3390/jpm12040623] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Yamai T, Ikezawa K, Kawamoto Y, Hirao T, Higashi S, Daiku K, Maeda S, Abe Y, Urabe M, Kai Y, Takada R, Nakabori T, Uehara H, Ohkawa K. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice. Current Oncology 2022;29:2644-9. [DOI: 10.3390/curroncol29040216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
153 Ortega MA, Fraile-martinez O, Pekarek L, García-montero C, Alvarez-mon MA, Castellanos AJ, García-honduvilla N, Buján J, Alvarez-mon M, Sáez MA, Guijarro LG, Asúnsolo A. Oxidative Stress Markers Are Associated with a Poor Prognosis in Patients with Pancreatic Cancer. Antioxidants 2022;11:759. [DOI: 10.3390/antiox11040759] [Reference Citation Analysis]
154 Zhang L, Sun L, Tang Q, Sun S, Zeng L, Ma J, Li X, Ge H, Liang X. Cascade Drug Delivery through Tumor Barriers of Pancreatic Cancer via Ultrasound in Combination with Functional Microbubbles. ACS Biomater Sci Eng 2022;8:1583-95. [PMID: 35263095 DOI: 10.1021/acsbiomaterials.2c00069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Ono M, Ono Y, Nakamura T, Tsuchikawa T, Kuraya T, Kuwabara S, Nakanishi Y, Asano T, Matsui A, Tanaka K, Ebihara Y, Kurashima Y, Noji T, Murakami S, Shichinohe T, Mitsuhashi T, Omori Y, Furukawa T, Taniue K, Suzuki M, Sugitani A, Karasaki H, Mizukami Y, Hirano S. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9. Ann Surg Oncol. [DOI: 10.1245/s10434-022-11630-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Liu SS, Ouyang YJ, Lu XZ. Potential roles of exosomal non-coding RNAs in chemoresistance in pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2022; 30(7): 303-309 [DOI: 10.11569/wcjd.v30.i7.303] [Reference Citation Analysis]
157 Chen Y, Yin B, Liu Z, Wang H, Fu Z, Ji X, Tang W, Ni D, Peng W. Dual-modality magnetic resonance/optical imaging-guided sonodynamic therapy of pancreatic cancer with metal—organic nanosonosensitizer. Nano Res . [DOI: 10.1007/s12274-022-4284-8] [Reference Citation Analysis]
158 Pan S, Qin T, Yin T, Yu X, Li J, Liu J, Zhao W, Chen X, Li D, Liu J, Li J, Liu Y, Zhu F, Wang M, Zhang H, Qin R; Minimally Invasive Treatment Group in the Pancreatic Disease Branch of China’s International Exchange and Promotion Association for Medicine and Healthcare (MITG-P-CPAM). Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: study protocol for a multicentre randomised controlled trial. BMJ Open 2022;12:e057128. [PMID: 35379633 DOI: 10.1136/bmjopen-2021-057128] [Reference Citation Analysis]
159 Deng S, Luo J, Ouyang Y, Xie J, He Z, Huang B, Bai F, Xiao K, Yin B, Wang J, Xu B, Zuo C. Application analysis of omental flap isolation and modified pancreaticojejunostomy in pancreaticoduodenectomy (175 cases). BMC Surg 2022;22. [DOI: 10.1186/s12893-022-01552-9] [Reference Citation Analysis]
160 Zhang G, Li N, Qi Y, Zhao Q, Zhan J, Yu D. Synergistic ferroptosis-gemcitabine chemotherapy of the gemcitabine loaded carbonaceous nanozymes to enhance the treatment and magnetic resonance imaging monitoring of pancreatic cancer. Acta Biomater 2022;142:284-97. [PMID: 35151925 DOI: 10.1016/j.actbio.2022.02.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Chen J, Chen H, Zhang T, Yin X, Man J, Yang X, Lu M. Burden of pancreatic cancer along with attributable risk factors in China from 1990 to 2019, and projections until 2030. Pancreatology 2022. [DOI: 10.1016/j.pan.2022.04.011] [Reference Citation Analysis]
162 Huang X, Zhang G, Liang T. Subtyping for pancreatic cancer precision therapy. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Cui W, Zhang J, Wu D, Zhang J, Zhou H, Rong Y, Liu F, Wei B, Xu X. Ponicidin suppresses pancreatic cancer growth by inducing ferroptosis: Insight gained by mass spectrometry-based metabolomics. Phytomedicine 2022;98:153943. [DOI: 10.1016/j.phymed.2022.153943] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
164 Li D, Wang L, Cai W, Liang M, Ma X, Zhao X. Prognostic stratification in patients with pancreatic ductal adenocarcinoma after curative resection based on preoperative pancreatic contrast-enhanced CT findings. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110313] [Reference Citation Analysis]
165 Turner KM, Delman AM, Ammann AM, Sohal D, Olowokure O, Choe KA, Smith MT, Kharofa JR, Ahmad SA, Wilson GC, Patel SH. Is There a Benefit to Adjuvant Chemotherapy in Resected, Early Stage Pancreatic Ductal Adenocarcinoma? Ann Surg Oncol 2022. [PMID: 35357614 DOI: 10.1245/s10434-022-11580-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Damiani V, Cufaro MC, Fucito M, Dufrusine B, Rossi C, Del Boccio P, Federici L, Turco MC, Sallese M, Pieragostino D, De Laurenzi V. Proteomics Approach Highlights Early Changes in Human Fibroblasts-Pancreatic Ductal Adenocarcinoma Cells Crosstalk. Cells 2022;11:1160. [PMID: 35406724 DOI: 10.3390/cells11071160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Shi S, Ye L, Jin K, Xiao Z, Yu X, Wu W. Innate Lymphoid Cells: Emerging Players in Pancreatic Disease. Int J Mol Sci 2022;23:3748. [PMID: 35409105 DOI: 10.3390/ijms23073748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Wu Z, Xu J, Tang R, Wang W, Zhang B, Yu X, Liu J, Shi S, Xu Y. The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. Journal of Oncology 2022;2022:1-16. [DOI: 10.1155/2022/4148805] [Reference Citation Analysis]
169 Yang Z, Shi G, Zhang P. Development and Validation of Nomograms to Predict Overall Survival and Cancer-Specific Survival in Patients With Pancreatic Adenosquamous Carcinoma. Front Oncol 2022;12:831649. [PMID: 35330710 DOI: 10.3389/fonc.2022.831649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Cao W, Tian R, Pan R, Sun B, Xiao C, Chen Y, Zeng Z, Lei S. Terpinen-4-ol inhibits the proliferation and mobility of pancreatic cancer cells by downregulating Rho-associated coiled-coil containing protein kinase 2. Bioengineered 2022;13:8643-56. [PMID: 35322742 DOI: 10.1080/21655979.2022.2054205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Krstic A, Pavic A, Avdovic E, Markovic Z, Stevanovic M, Petrovic I. Coumarin-Palladium(II) Complex Acts as a Potent and Non-Toxic Anticancer Agent against Pancreatic Carcinoma Cells. Molecules 2022;27:2115. [PMID: 35408514 DOI: 10.3390/molecules27072115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
172 Simoni N, Rossi G, Cellini F, Vitolo V, Orlandi E, Valentini V, Mazzarotto R, Sverzellati N, D’abbiero N. Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm? Life 2022;12:465. [DOI: 10.3390/life12040465] [Reference Citation Analysis]
173 Gouirand V, Gicquel T, Lien EC, Jaune-Pons E, Da Costa Q, Finetti P, Metay E, Duluc C, Mayers JR, Audebert S, Camoin L, Borge L, Rubis M, Leca J, Nigri J, Bertucci F, Dusetti N, Lucio Iovanna J, Tomasini R, Bidaut G, Guillaumond F, Vander Heiden MG, Vasseur S. Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. EMBO J 2022;:e110466. [PMID: 35307861 DOI: 10.15252/embj.2021110466] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
174 Smith ES, Whitty E, Yoo B, Moore A, Sempere LF, Medarova Z. Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine. Cancers (Basel) 2022;14:1588. [PMID: 35326738 DOI: 10.3390/cancers14061588] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
175 Shi Z, Yang J, Kong W, Qiu X, Lu C, Liu J, Liu B, Du J. Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer. Front Oncol 2022;12:782730. [PMID: 35299738 DOI: 10.3389/fonc.2022.782730] [Reference Citation Analysis]
176 Liang Z, Tang S, He R, Luo W, Qin S, Jiang H. The effect and mechanism of miR-30e-5p targeting SNAI1 to regulate epithelial-mesenchymal transition on pancreatic cancer. Bioengineered 2022;13:8013-28. [PMID: 35300562 DOI: 10.1080/21655979.2022.2050880] [Reference Citation Analysis]
177 Yang C, Li J, Guo Y, Gan D, Zhang C, Wang R, Hua L, Zhu L, Ma P, Shi J, Li S, Su H. Role of TFRC as a Novel Prognostic Biomarker and in Immunotherapy for Pancreatic Carcinoma. Front Mol Biosci 2022;9:756895. [DOI: 10.3389/fmolb.2022.756895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
178 Tang T, Huang X, Zhang G, Lu M, Hong Z, Wang M, Huang J, Zhi X, Liang T. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. J Immunother Cancer 2022;10:e004129. [PMID: 35288467 DOI: 10.1136/jitc-2021-004129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Rossi G, Altabella L, Simoni N, Benetti G, Rossi R, Venezia M, Paiella S, Malleo G, Salvia R, Guariglia S, Bassi C, Cavedon C, Mazzarotto R. Computed tomography-based radiomic to predict resectability in locally advanced pancreatic cancer treated with chemotherapy and radiotherapy. World J Gastrointest Oncol 2022; 14(3): 703-715 [DOI: 10.4251/wjgo.v14.i3.703] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Hai H, Li Z, Zhang Z, Cheng Y, Liu Z, Gong J, Deng Y. Duct-to-mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy. Cochrane Database Syst Rev 2022;3:CD013462. [PMID: 35289922 DOI: 10.1002/14651858.CD013462.pub2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
181 Hu J, Jiang J, Liu R, Cheng M, Zhu G, He S, Shi B, Zhao Y, He Z, Yu H, Zhang X, Zheng H, Hua B. Clinical Efficacy and Safety of Traditional Medicine Preparations Combined With Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Front Oncol 2022;12:828450. [PMID: 35280766 DOI: 10.3389/fonc.2022.828450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Guo H, Xiao Y, Yuan Z, Yang X, Chen J, Chen C, Wang M, Xie L, Chen Q, Tong Y, Zhang Q, Bai Y. Inhibition of STAT3Y705 phosphorylation by Stattic suppresses proliferation and induces mitochondrial-dependent apoptosis in pancreatic cancer cells. Cell Death Discov 2022;8:116. [PMID: 35288541 DOI: 10.1038/s41420-022-00922-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
183 Takikawa T, Kikuta K, Hamada S, Kume K, Miura S, Yoshida N, Tanaka Y, Matsumoto R, Ikeda M, Kataoka F, Sasaki A, Nakagawa K, Unno M, Masamune A. Clinical features and prognostic impact of asymptomatic pancreatic cancer. Sci Rep 2022;12:4262. [PMID: 35277545 DOI: 10.1038/s41598-022-08083-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
184 Qi S, Guan X, Zhang J, Yu D, Yu X, Li Q, Yin W, Cheng XD, Zhang W, Qin JJ. Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis. Mol Cancer 2022;21:70. [PMID: 35272681 DOI: 10.1186/s12943-022-01538-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 El Haddaoui H, Brood R, Latifi D, Oostvogels AA, Klaver Y, Moskie M, Mustafa DA, Debets R, van Eijck CHJ. Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program. Cancers (Basel) 2022;14:1377. [PMID: 35326528 DOI: 10.3390/cancers14061377] [Reference Citation Analysis]
186 Yu T, Tan H, Liu C, Nie W, Wang Y, Zhou K, Shi H. Integratively Genomic Analysis Reveals the Prognostic and Immunological Characteristics of Pyroptosis and Ferroptosis in Pancreatic Cancer for Precision Immunotherapy. Front Cell Dev Biol 2022;10:826879. [PMID: 35242763 DOI: 10.3389/fcell.2022.826879] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
187 Wang H, Zhou H, Ni H, Shen X. COL11A1-Driven Epithelial–Mesenchymal Transition and Stemness of Pancreatic Cancer Cells Induce Cell Migration and Invasion by Modulating the AKT/GSK-3β/Snail Pathway. Biomolecules 2022;12:391. [DOI: 10.3390/biom12030391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
188 Wang L, Liu Z, Zhu R, Liang R, Wang W, Li J, Zhang Y, Guo C, Han X, Sun Y. Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: implications for risk stratification and frontline therapies in pancreatic cancer. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.02.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
189 Nan P, Dong X, Bai X, Lu H, Liu F, Sun Y, Zhao X. Tumor-stroma TGF-β1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin αvβ3/CD36-mediated activation of the MAPK pathway. Cancer Letters 2022;528:59-75. [DOI: 10.1016/j.canlet.2021.12.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
190 Zhang X, Mao T, Zhang B, Xu H, Cui J, Jiao F, Chen D, Wang Y, Hu J, Xia Q, Ge W, Li S, Yue M, Ma J, Yao J, Wang Y, Wang Y, Shentu D, Zhang X, Chen S, Bai Y, Wang Y, Zhang X, Liu Q, Sun Y, Fu D, Liu Y, Xiong L, Wang L. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. EBioMedicine 2022;77:103897. [PMID: 35231699 DOI: 10.1016/j.ebiom.2022.103897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
191 Chen Y, Liu Y, Wang M. Identification of a Pyroptosis-Related Gene Signature and Effect of Silencing the CHMP4C and CASP4 in Pancreatic Adenocarcinoma. IJGM 2022;Volume 15:3199-213. [DOI: 10.2147/ijgm.s353849] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Zhao Y, Yang M, Wang S, Abbas SJ, Zhang J, Li Y, Shao R, Liu Y. An Overview of Epigenetic Methylation in Pancreatic Cancer Progression. Front Oncol 2022;12:854773. [DOI: 10.3389/fonc.2022.854773] [Reference Citation Analysis]
193 Zhang X, Ren Z, Xu J, Chen Q, Ma J, Liu Z, Kou J, Zhao X, Lang R, He Q, Acharya B. MiR-1301-3p Inhibits Epithelial-Mesenchymal Transition via Targeting RhoA in Pancreatic Cancer. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/5514715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
194 Gao KF, Zhao YF, Liao WJ, Xu GL, Zhang JD. CERS6-AS1 promotes cell proliferation and represses cell apoptosis in pancreatic cancer via miR-195-5p/WIPI2 axis. Kaohsiung J Med Sci 2022. [PMID: 35199935 DOI: 10.1002/kjm2.12522] [Reference Citation Analysis]
195 Wu Q, Chen L, Miao D, Jin Y, Zhu Z. Prognostic signature based on m6A-related lncRNAs to predict overall survival in pancreatic ductal adenocarcinoma. Sci Rep 2022;12:3079. [PMID: 35197523 DOI: 10.1038/s41598-022-07112-8] [Reference Citation Analysis]
196 Zhao X, Li Z, Gu Z. A new era: tumor microenvironment in chemoresistance of pancreatic cancer. J Cancer Sci Clin Ther 2022;6:61-86. [PMID: 35187493 DOI: 10.26502/jcsct.5079146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Li S, Zhang G, Lu Y, Zhao T, Gao C, Liu W, Piao Y, Chen Y, Huang C, Chang A, Hao J. Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer. Front Oncol 2022;12:841819. [DOI: 10.3389/fonc.2022.841819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Waldenmaier M, Schulte L, Schönfelder J, Fürstberger A, Kraus JM, Daiss N, Seibold T, Morawe M, Ettrich TJ, Kestler HA, Kahlert C, Seufferlein T, Eiseler T. Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients. Cancers (Basel) 2022;14:1074. [PMID: 35205822 DOI: 10.3390/cancers14041074] [Reference Citation Analysis]
199 Liu Y, Wang X, Zhu Y, Cao Y, Wang L, Li F, Zhang Y, Li Y, Zhang Z, Luo J, Deng X, Peng C, Wei G, Chen H, Shen B. The CTCF/LncRNA‐PACERR complex recruits E1A binding protein p300 to induce pro‐tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating PTGS2 expression. Clinical & Translational Med 2022;12. [DOI: 10.1002/ctm2.654] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
200 Shi X, Yang J, Liu M, Zhang Y, Zhou Z, Luo W, Fung KM, Xu C, Bronze MS, Houchen CW, Li M. Circular RNA ANAPC7 Inhibits Tumor Growth and Muscle Wasting via PHLPP2-AKT-TGF-β Signaling Axis in Pancreatic Cancer. Gastroenterology 2022;162:2004-2017.e2. [PMID: 35176309 DOI: 10.1053/j.gastro.2022.02.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
201 Wang M, Hu Q, Huang J, Zhao X, Shao S, Zhang F, Yao Z, Ping Y, Liang T. Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy. J Nanobiotechnology 2022;20:85. [PMID: 35177078 DOI: 10.1186/s12951-022-01282-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
202 Wang X, Li L, Yang Y, Fan L, Ma Y, Mao F. Reveal the Heterogeneity in the Tumor Microenvironment of Pancreatic Cancer and Analyze the Differences in Prognosis and Immunotherapy Responses of Distinct Immune Subtypes. Front Oncol 2022;12:832715. [DOI: 10.3389/fonc.2022.832715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
203 Li J, Zhang J, Tao S, Hong J, Zhang Y, Chen W. Prognostication of Pancreatic Cancer Using The Cancer Genome Atlas Based Ferroptosis-Related Long Non-Coding RNAs. Front Genet 2022;13:838021. [DOI: 10.3389/fgene.2022.838021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Wang Z, He D, Chen C, Liu X, Ke N. Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report. Front Oncol 2021;11:801320. [PMID: 35145907 DOI: 10.3389/fonc.2021.801320] [Reference Citation Analysis]
205 He J, Lin X, Meng F, Zhao Y, Wang W, Zhang Y, Chai X, Zhang Y, Yu W, Yang J, Li G, Du X, Zhang H, Liu M, Lu W. A Novel Small Molecular Prostaglandin Receptor EP4 Antagonist, L001, Suppresses Pancreatic Cancer Metastasis. Molecules 2022;27:1209. [DOI: 10.3390/molecules27041209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
206 Xiao W, Cao R, Yang W, Tan J, Liu R, Kan H, Zhou L, Zhang N, Chen Z, Chen X, Xu J, Zhang G, Shen P. Roles and Clinical Significances of ATF6, EMC6, and APAF1 in Prognosis of Pancreatic Cancer. Front Genet 2022;12:730847. [DOI: 10.3389/fgene.2021.730847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
207 Sasaki T, Nishiwada S, Nakagawa K, Nagai M, Terai T, Hokuto D, Yasuda S, Matsuo Y, Doi S, Sho M. Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer. Int J Clin Oncol 2022. [PMID: 35142963 DOI: 10.1007/s10147-022-02131-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Slapak EJ, el Mandili M, Bijlsma MF, Spek CA. Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview. Pharmaceutics 2022;14:390. [DOI: 10.3390/pharmaceutics14020390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
209 Liu L, Huang X, Shi F, Song J, Guo C, Yang J, Liang T, Bai X. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. J Exp Clin Cancer Res 2022;41:56. [PMID: 35139879 DOI: 10.1186/s13046-022-02273-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
210 Vietri MT, D’elia G, Caliendo G, Albanese L, Signoriello G, Napoli C, Molinari AM. Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation. Genes 2022;13:321. [DOI: 10.3390/genes13020321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
211 Zhang Y, Sun J, Song Y, Gao P, Wang X, Chen M, Li Y, Wu Z. Roles of fusion genes in digestive system cancers: dawn for cancer precision therapy. Crit Rev Oncol Hematol 2022;:103622. [PMID: 35124200 DOI: 10.1016/j.critrevonc.2022.103622] [Reference Citation Analysis]
212 Zheng T, Han W, Wang A, Wang Y. Functional mechanism of hsa-miR-128-3p in epithelial-mesenchymal transition of pancreatic cancer cells via ZEB1 regulation. PeerJ 2022;10:e12802. [DOI: 10.7717/peerj.12802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
213 Gray S, de Liguori Carino N, Radhakrishna G, Lamarca A, Hubner RA, Valle JW, Mcnamara MG. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.02.014] [Reference Citation Analysis]
214 Zhang Z, Zhou N, Guo X, Li N, Zhu H, Yang Z. Pretherapeutic Assessment of Pancreatic Cancer: Comparison of FDG PET/CT Plus Delayed PET/MR and Contrast-Enhanced CT/MR. Front Oncol 2021;11:790462. [PMID: 35096590 DOI: 10.3389/fonc.2021.790462] [Reference Citation Analysis]
215 Tang H, Xue Y, Li B, Xu X, Zhang F, Guo J, Li Q, Yuan T, Chen Y, Pan Y, Ping Y, Li D. Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with siRNA against patient-derived pancreatic carcinoma. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.02.007] [Reference Citation Analysis]
216 Schreyer D, Neoptolemos JP, Barry ST, Bailey P. Deconstructing Pancreatic Cancer Using Next Generation-Omic Technologies-From Discovery to Knowledge-Guided Platforms for Better Patient Management. Front Cell Dev Biol 2021;9:795735. [PMID: 35096825 DOI: 10.3389/fcell.2021.795735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
217 Zhang F, Wang Y, Yang F, Zhang Y, Jiang M, Zhang X. The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study. CMAR 2022;Volume 14:535-46. [DOI: 10.2147/cmar.s349442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Tadehara M, Kato T, Adachi K, Tamaki A, Kesen Y, Sakurai Y, Ichinoe M, Koizumi W, Murakumo Y. Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With Anticancer Drug Sensitivity in Pancreatic Cancer Cells. Pancreas 2022;51:183-9. [DOI: 10.1097/mpa.0000000000001975] [Reference Citation Analysis]
219 Desai N, Besaw RJ, Sedhom R, Qasim Hussaini SM, Blaes AH, Dusetzina SB, Gupta A. Estimated out-of-pocket costs for cancer-directed and supportive care medications for older adults with advanced pancreatic cancer. Journal of Geriatric Oncology 2022. [DOI: 10.1016/j.jgo.2022.02.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Wang D, Ge H, Tian M, Li C, Zhao L, Pei Q, Tan F, Li Y, Ling C, Güngör C. The Survival Effect of Radiotherapy on Stage IIB/III Pancreatic Cancer Undergone Surgery in Different Age and Tumor Site Groups: A Propensity Scores Matching Analysis Based on SEER Database. Front Oncol 2022;12:799930. [DOI: 10.3389/fonc.2022.799930] [Reference Citation Analysis]
221 Palacios-Acedo AL, Langiu M, Crescence L, Mège D, Dubois C, Panicot-Dubois L. Platelet and Cancer-Cell Interactions Modulate Cancer-Associated Thrombosis Risk in Different Cancer Types. Cancers (Basel) 2022;14:730. [PMID: 35159000 DOI: 10.3390/cancers14030730] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
222 Chen G, Long J, Zhu R, Yang G, Qiu J, Zhao F, Liu Y, Tao J, Zhang T, Zhao Y. Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancer. Front Cell Dev Biol 2021;9:709669. [PMID: 35087823 DOI: 10.3389/fcell.2021.709669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Zu F, Chen H, Liu Q, Zang H, Li Z, Tan X. Syntenin Regulated by miR-216b Promotes Cancer Progression in Pancreatic Cancer. Front Oncol 2022;12:790788. [DOI: 10.3389/fonc.2022.790788] [Reference Citation Analysis]
224 Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Tienhoven G, van Eijck CHJ; Dutch Pancreatic Cancer Group. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol 2022;:JCO2102233. [PMID: 35084987 DOI: 10.1200/JCO.21.02233] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 31.0] [Reference Citation Analysis]
225 Mouratidis PXE, Ter Haar G. Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer. Cancers (Basel) 2022;14:638. [PMID: 35158903 DOI: 10.3390/cancers14030638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Xiao B, Zhang Y, Lu Z, Chen W, An Y, Zu G, Xu X, Wu D, Yang H, Qin Y, Chen X. A positive feedback loop of ARF6 activates ERK1/2 signaling pathway via DUSP6 silencing to promote pancreatic cancer progression. Acta Biochim Biophys Sin (Shanghai) 2022. [PMID: 36017891 DOI: 10.3724/abbs.2022111] [Reference Citation Analysis]
227 Mita J, Iguchi T, Iseda N, Takada K, Hirose K, Miura N, Honboh T, Emi Y, Akashi T, Kato S, Sadanaga N, Matsuura H. A case of successful conversion surgery for locally advanced pancreatic cancer with synchronous triple cancer of the lung and esophagus: a case report. surg case rep 2022;8. [DOI: 10.1186/s40792-022-01377-x] [Reference Citation Analysis]
228 Chen S, Guo W, Meng M, Wu D, Zhou T, Wang L, Xu J. LncRNA SNHG1 Promotes the Progression of Pancreatic Cancer by Regulating FGFR1 Expression via Competitively Binding to miR-497. Front Oncol 2022;12:813850. [DOI: 10.3389/fonc.2022.813850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
229 Gkountakos A, Simbolo M, Bariani E, Scarpa A, Luchini C. Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology. Int J Mol Sci 2022;23:1283. [PMID: 35163206 DOI: 10.3390/ijms23031283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Kartsonaki C, Pang Y, Millwood I, Yang L, Guo Y, Walters R, Lv J, Hill M, Yu C, Chen Y, Chen X, O’ Neill E, Chen J, Travis RC, Clarke R, Li L, Chen Z, Holmes MV. Circulating proteins and risk of pancreatic cancer: a case-subcohort study among Chinese adults. International Journal of Epidemiology 2022. [DOI: 10.1093/ije/dyab274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
231 Wang X, Dou X, Ren X, Rong Z, Sun L, Deng Y, Chen P, Li Z. A Ductal-Cell-Related Risk Model Integrating Single-Cell and Bulk Sequencing Data Predicts the Prognosis of Patients With Pancreatic Adenocarcinoma. Front Genet 2021;12:763636. [PMID: 35047000 DOI: 10.3389/fgene.2021.763636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Liu Y, Li G, Yang Y, Lu Z, Wang T, Wang X, Liu J. Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma. Front Genet 2021;12:752025. [PMID: 35046996 DOI: 10.3389/fgene.2021.752025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
233 Roalsø MTT, Hald ØH, Alexeeva M, Søreide K. Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma. Cancers 2022;14:546. [DOI: 10.3390/cancers14030546] [Reference Citation Analysis]
234 Geleta B, Tout FS, Lim SC, Sahni S, Jansson PJ, Apte MV, Richardson DR, Kovačević Ž. Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1. J Biol Chem 2022;298:101608. [PMID: 35065073 DOI: 10.1016/j.jbc.2022.101608] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
235 Ren H, Zeng X, Zhao X, Hou D, Yao H, Yaseen M, Zhao L, Xu W, Wang H, Li L. A bioactivated in vivo assembly nanotechnology fabricated NIR probe for small pancreatic tumor intraoperative imaging. Nat Commun 2022;13. [DOI: 10.1038/s41467-021-27932-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
236 Cao Y, Zhao R, Guo K, Ren S, Zhang Y, Lu Z, Tian L, Li T, Chen X, Wang Z. Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma. Front Oncol 2022;11:744667. [DOI: 10.3389/fonc.2021.744667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Chen H, Zu F, Zeng T, Chen Z, Wei J, Liu P, Li Z, Zhou L, Wang H, Tan H, Tan X. Prognostic Value and Correlation With Tumor Immune Infiltration of a Novel Metabolism-Related Gene Signature in Pancreatic Cancer. Front Oncol 2022;11:757791. [DOI: 10.3389/fonc.2021.757791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Bellomo G, Rainer C, Quaranta V, Astuti Y, Raymant M, Boyd E, Stafferton R, Campbell F, Ghaneh P, Halloran CM, Hammond DE, Morton JP, Palmer D, Vimalachandran D, Jones R, Mielgo A, Schmid MC. Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. Gut 2022:gutjnl-2021-325272. [PMID: 35022267 DOI: 10.1136/gutjnl-2021-325272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
239 Iwano T, Yoshimura K, Watanabe G, Saito R, Kiritani S, Kawaida H, Moriguchi T, Murata T, Ogata K, Ichikawa D, Arita J, Hasegawa K, Takeda S. High-performance Collective Biomarker from Liquid Biopsy for Diagnosis of Pancreatic Cancer Based on Mass Spectrometry and Machine Learning. J Cancer 2021;12:7477-87. [PMID: 35003367 DOI: 10.7150/jca.63244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Gheorghe G, Diaconu CC, Ionescu V, Constantinescu G, Bacalbasa N, Bungau S, Gaman M, Stan-ilie M. Risk Factors for Pancreatic Cancer: Emerging Role of Viral Hepatitis. JPM 2022;12:83. [DOI: 10.3390/jpm12010083] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Xiang XS, Li PC, Wang WQ, Liu L. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. Biochim Biophys Acta Rev Cancer 2022;1877:188676. [PMID: 35016922 DOI: 10.1016/j.bbcan.2022.188676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Chen J, Yao D, Chen W, Li Z, Guo Y, Zhu F, Hu X. Serum exosomal miR-451a acts as a candidate marker for pancreatic cancer. Int J Biol Markers 2022;:17246008211070018. [PMID: 35001683 DOI: 10.1177/17246008211070018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
243 Tang P, Qu W, Wu D, Chen S, Liu M, Chen W, Ai Q, Tang H, Zhou H. Identifying and Validating an Acidosis-Related Signature Associated with Prognosis and Tumor Immune Infiltration Characteristics in Pancreatic Carcinoma. J Immunol Res 2021;2021:3821055. [PMID: 34993253 DOI: 10.1155/2021/3821055] [Reference Citation Analysis]
244 Zhang Z, Zhang H, Liu T, Chen T, Wang D, Tang D. Heterogeneous Pancreatic Stellate Cells Are Powerful Contributors to the Malignant Progression of Pancreatic Cancer. Front Cell Dev Biol 2021;9:783617. [PMID: 34988078 DOI: 10.3389/fcell.2021.783617] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
245 Gupta A, Virnig BA, Nipp RD. Opioid Prescriptions and Survival in Pancreatic Cancer. JCO Oncol Pract 2022;:OP2100862. [PMID: 34990288 DOI: 10.1200/OP.21.00862] [Reference Citation Analysis]
246 Huang XD, Xiao FJ, Guo YT, Sun Y, Zhang YK, Shi XJ. Protein tyrosine phosphatase 1 protects human pancreatic cancer from erastin-induced ferroptosis. Asian J Surg 2022:S1015-9584(21)00789-2. [PMID: 35000852 DOI: 10.1016/j.asjsur.2021.11.048] [Reference Citation Analysis]
247 Won EJ, Park H, Yoon TJ, Cho YS. Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics. Pharmaceutics 2022;14:137. [PMID: 35057033 DOI: 10.3390/pharmaceutics14010137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Yang Y, Shi XQ, Chen G, Zhou XN, Qian LX. Contrast-enhanced ultrasound for evaluating response to pulsed-wave high-intensity focused ultrasound therapy in advanced pancreatic cancer. Clin Hemorheol Microcirc 2022. [PMID: 35001881 DOI: 10.3233/CH-211342] [Reference Citation Analysis]
249 Coriat R, Pellat A. Updates on the Treatment of Pancreatic Diseases: Focus on Surgery, Electrochemotherapy and Rituximab. J Clin Med 2022;11:239. [PMID: 35011980 DOI: 10.3390/jcm11010239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
250 Yamada Y, Sasaki T, Takeda T, Okamoto T, Takamatsu M, Mori C, Mie T, Furukawa T, Kasuga A, Matsuyama M, Ozaka M, Igarashi Y, Sasahira N. A Case of Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. Intern Med . [DOI: 10.2169/internalmedicine.8848-21] [Reference Citation Analysis]
251 Zhang C, Xin L, Li J, Cao J, Sun Y, Wang X, Luo J, Zeng Y, Li Q, Zhang Y, Zhang T, Huang P. Metal-Organic Framework (MOF)-Based Ultrasound-Responsive Dual-Sonosensitizer Nanoplatform for Hypoxic Cancer Therapy. Adv Healthc Mater 2022;11:e2101946. [PMID: 34706160 DOI: 10.1002/adhm.202101946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
252 Lu Z, Shao W, Shi X, Tan T, Xing C, Li Z, Xu J, Cui H, Song J. Identifying optimal candidates for tumor resection among borderline and locally advanced pancreatic cancer: A population-based predictive model. Pancreatology 2022. [DOI: 10.1016/j.pan.2022.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Huang J, Mao Q, Sun X. Identification of a DNA repair 9-gene signature for the overall survival prediction of pancreatic cancer. Annals of Diagnostic Pathology 2022. [DOI: 10.1016/j.anndiagpath.2021.151883] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Mattiolo P, Kryklyva V, Brosens LA, Mafficini A, Lawlor RT, Milella M, Scarpa A, Corbo V, Luchini C. Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. Expert Opinion on Therapeutic Targets. [DOI: 10.1080/14728222.2022.2021397] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
255 Cortesi M, Zanoni M, Pirini F, Tumedei MM, Ravaioli S, Rapposelli IG, Frassineti GL, Bravaccini S. Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight. Int J Mol Sci 2021;23:254. [PMID: 35008679 DOI: 10.3390/ijms23010254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
256 Yan J, Yuan P, Gui L, Wang Z, Yin P, Gao WQ, Ma B. CCL28 Downregulation Attenuates Pancreatic Cancer Progression Through Tumor Cell-Intrinsic and -Extrinsic Mechanisms. Technol Cancer Res Treat 2021;20:15330338211068958. [PMID: 34939465 DOI: 10.1177/15330338211068958] [Reference Citation Analysis]
257 Shen C, Roth HR, Hayashi Y, Oda M, Miyamoto T, Sato G, Mori K. A cascaded fully convolutional network framework for dilated pancreatic duct segmentation. Int J Comput Assist Radiol Surg 2021. [PMID: 34951681 DOI: 10.1007/s11548-021-02530-x] [Reference Citation Analysis]
258 Zhuang H, Wang S, Chen B, Zhang Z, Ma Z, Li Z, Liu C, Zhou Z, Gong Y, Huang S, Hou B, Chen Y, Zhang C. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas. Front Immunol 2021;12:790661. [PMID: 34925373 DOI: 10.3389/fimmu.2021.790661] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
259 Ota S, Miyashita M, Yamagishi Y, Ogasawara M. Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy. Hum Vaccin Immunother 2021;:1-10. [PMID: 34919493 DOI: 10.1080/21645515.2021.2003645] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
260 Faleiro I, Roberto VP, Demirkol Canli S, Fraunhoffer NA, Iovanna J, Gure AO, Link W, Castelo-branco P. DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study. Cancers 2021;13:6354. [DOI: 10.3390/cancers13246354] [Reference Citation Analysis]
261 Cao D, Song Q, Li J, Jiang Y, Wang Z, Lu S. Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer. Expert Rev Mol Med 2021;23:e21. [PMID: 34906271 DOI: 10.1017/erm.2021.26] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
262 Brown TJ, Reiss KA. PARP Inhibitors in Pancreatic Cancer. Cancer J 2021;27:465-75. [PMID: 34904809 DOI: 10.1097/PPO.0000000000000554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Liu Y, Cheng L, Song X, Li C, Zhang J, Wang L. A TP53-associated immune prognostic signature for the prediction of the overall survival and therapeutic responses in pancreatic cancer. Math Biosci Eng 2022;19:191-208. [PMID: 34902987 DOI: 10.3934/mbe.2022010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
264 Zhang Z, Yin T, Qin T, Pan S, Wang M, Zhang H, Qin R. Comparison of laparoscopic versus open pancreaticoduodenectomy in patients with resectable pancreatic ductal adenocarcinoma: A propensity score-matching analysis of long-term survival. Pancreatology 2021:S1424-3903(21)00652-9. [PMID: 34969601 DOI: 10.1016/j.pan.2021.12.005] [Reference Citation Analysis]
265 Vaish U, Jain T, Are AC, Dudeja V. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting. Int J Mol Sci 2021;22:13408. [PMID: 34948209 DOI: 10.3390/ijms222413408] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
266 Rizzo A, Ricci AD, Lanotte L, Lombardi L, Di Federico A, Brandi G, Gadaleta-Caldarola G. Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opin Investig Drugs 2021;:1-9. [PMID: 34802383 DOI: 10.1080/13543784.2022.2009456] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
267 Chen Y, Wang C, Song J, Xu R, Ruze R, Zhao Y. S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer. Front Immunol 2021;12:758004. [PMID: 34887861 DOI: 10.3389/fimmu.2021.758004] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
268 Nicolle R, Gayet O, Bigonnet M, Roques J, Chanez B, Puleo F, Augustin J, Emile JF, Svrcek M, Arsenijevic T, Hammel P, Rebours V, Giovannini M, Grandval P, Dahan L, Moutardier V, Mitry E, Van Laethem JL, Bachet JB, Cros J, Iovanna J, Dusetti NJ. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer. Transl Oncol 2021;16:101315. [PMID: 34906890 DOI: 10.1016/j.tranon.2021.101315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
269 Jin Y, Zhang Z, Yu Q, Zeng Z, Song H, Huang X, Kong Q, Hu H, Xia Y. Positive Reciprocal Feedback of lncRNA ZEB1-AS1 and HIF-1α Contributes to Hypoxia-Promoted Tumorigenesis and Metastasis of Pancreatic Cancer. Front Oncol 2021;11:761979. [PMID: 34881179 DOI: 10.3389/fonc.2021.761979] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
270 Narayanan S, Vicent S, Ponz-sarvisé M. PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem? Front Cell Dev Biol 2021;9:787249. [DOI: 10.3389/fcell.2021.787249] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
271 Xu J, Cheng K, Lin H, Han W, He T, Nie X, Sun Y, Qiuman S, Reheman Y, Chen Q. Characterization of the GATA Transcription Factor Family and Exploration of Their Relevance to Immune Infiltration and Tumor Microenvironment in Pancreatic Cancer. Int J Gen Med 2021;14:9083-101. [PMID: 34876843 DOI: 10.2147/IJGM.S342741] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
272 Zhang Z, Zhang HJ. Glycometabolic rearrangements-aerobic glycolysis in pancreatic ductal adenocarcinoma (PDAC): roles, regulatory networks, and therapeutic potential. Expert Opin Ther Targets 2021;:1-17. [PMID: 34874212 DOI: 10.1080/14728222.2021.2015321] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
273 Li JA, Rong Y, Mao W, Zhang L, Kuang T, Lou W. Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdown in pancreatic cancer. Cell Cycle 2021;:1-20. [PMID: 34874801 DOI: 10.1080/15384101.2021.2014254] [Reference Citation Analysis]
274 Tang S, Hang Y, Ding L, Tang W, Yu A, Zhang C, Sil D, Xie Y, Oupický D. Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer. Mol Pharm 2021;18:4448-58. [PMID: 34699242 DOI: 10.1021/acs.molpharmaceut.1c00653] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
275 Carvalho TMA, Di Molfetta D, Greco MR, Koltai T, Alfarouk KO, Reshkin SJ, Cardone RA. Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches. Cancers (Basel) 2021;13:6135. [PMID: 34885243 DOI: 10.3390/cancers13236135] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
276 Wang B, Yang L, Liu T, Xun J, Zhuo Y, Zhang L, Zhang Q, Wang X. Hydroxytyrosol Inhibits MDSCs and Promotes M1 Macrophages in Mice With Orthotopic Pancreatic Tumor. Front Pharmacol 2021;12:759172. [PMID: 34858184 DOI: 10.3389/fphar.2021.759172] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
277 Barros AG, Pulido CF, Machado M, Brito MJ, Couto N, Sousa O, Melo SA, Mansinho H. Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). Int J Oncol 2021;59:110. [PMID: 34859257 DOI: 10.3892/ijo.2021.5290] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
278 Mohseni G, Li J, Ariston Gabriel AN, Du L, Wang YS, Wang C. The Function of cGAS-STING Pathway in Treatment of Pancreatic Cancer. Front Immunol 2021;12:781032. [PMID: 34858438 DOI: 10.3389/fimmu.2021.781032] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
279 Balzan SMP, Gava VG, Rieger A, Magalhães MA, Schwengber A, Ferreira F. Falciform ligament tubular graft for mesenteric-portal vein reconstruction during pancreaticoduodenectomy. J Surg Oncol 2021. [PMID: 34862611 DOI: 10.1002/jso.26762] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
280 van Dam MA, Vuijk FA, Stibbe JA, Houvast RD, Luelmo SAC, Crobach S, Shahbazi Feshtali S, de Geus-Oei LF, Bonsing BA, Sier CFM, Kuppen PJK, Swijnenburg RJ, Windhorst AD, Burggraaf J, Vahrmeijer AL, Mieog JSD. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Cancers (Basel) 2021;13:6088. [PMID: 34885196 DOI: 10.3390/cancers13236088] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
281 Rubinson D, Wolpin BM, Warsofsky IS, Ryan DP, Perez K, Rahma O, Singh H, Yurgelun MB, Shapiro GI, Aguirre AJ, D'Andrea AD, Cleary JM. Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. J Gastrointest Oncol 2021;12:3133-40. [PMID: 35070436 DOI: 10.21037/jgo-21-197] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Cong M, Xu G, Yang S, Zhang J, Zhang W, Dhumal D, Laurini E, Zhang K, Xia Y, Pricl S, Peng L, Zhao W. A self-assembling prodrug nanosystem to enhance metabolic stability and anticancer activity of gemcitabine. Chinese Chemical Letters 2021. [DOI: 10.1016/j.cclet.2021.11.083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
283 Sammallahti H, Kokkola A, Rezasoltani S, Ghanbari R, Asadzadeh Aghdaei H, Knuutila S, Puolakkainen P, Sarhadi VK. Microbiota Alterations and Their Association with Oncogenomic Changes in Pancreatic Cancer Patients. Int J Mol Sci 2021;22:12978. [PMID: 34884776 DOI: 10.3390/ijms222312978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
284 Halimi A, Gabarrini G, Sobkowiak MJ, Ateeb Z, Davanian H, Gaiser RA, Arnelo U, Valente R, Wong AYW, Moro CF, Del Chiaro M, Özenci V, Chen MS. Isolation of pancreatic microbiota from cystic precursors of pancreatic cancer with intracellular growth and DNA damaging properties. Gut Microbes 2021;13:1983101. [PMID: 34816784 DOI: 10.1080/19490976.2021.1983101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
285 Zhang X, Mao T, Zhang B, Xu H, Cui J, Jiao F, Chen D, Wang Y, Hu J, Xia Q, Li S, Yue M, Ma J, Yao J, Wang Y, Zhang X, Chen S, Bai Y, Wang Y, Zhang X, Liu Q, Sun Y, Fu D, Liu Y, Xiong L, Wang L. Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Cancer Commun (Lond) 2021. [PMID: 34821074 DOI: 10.1002/cac2.12238] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
286 Guo Y, Wang R, Li J, Song Y, Min J, Zhao T, Hua L, Shi J, Zhang C, Ma P, Yang C, Zhu L, Gan D, Li S, Liu X, Su H. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer. Front Immunol 2021;12:769425. [PMID: 34804059 DOI: 10.3389/fimmu.2021.769425] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
287 Xie X, Ji J, Chen X, Xu W, Chen H, Zhu S, Wu J, Wu Y, Sun Y, Sai W, Liu Z, Xiao M, Bao B. Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3. Clin Transl Oncol 2021. [PMID: 34811696 DOI: 10.1007/s12094-021-02705-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
288 Wang J, Lyu SC, Zhu JQ, Li XL, Lang R, He Q. Extended lymphadenectomy benefits patients with borderline resectable pancreatic head cancer-a single-center retrospective study. Gland Surg 2021;10:2910-24. [PMID: 34804879 DOI: 10.21037/gs-21-201] [Reference Citation Analysis]
289 Vernuccio F, Messina C, Merz V, Cannella R, Midiri M. Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. Diagnostics (Basel) 2021;11:2166. [PMID: 34829513 DOI: 10.3390/diagnostics11112166] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
290 Zhou X, Wang W, Li Z, Chen L, Wen C, Ruan Q, Xu Z, Liu R, Xu J, Bai Y, Deng J. Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling. Phytomedicine 2021;95:153861. [PMID: 34864627 DOI: 10.1016/j.phymed.2021.153861] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Shen Y, Zhu X, Cao F, Xie H, Ju X, Cao Y, Qing S, Jia Z, Gu L, Fang F, Zhang H. Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases. Front Oncol 2021;11:729490. [PMID: 34796108 DOI: 10.3389/fonc.2021.729490] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
292 Huh G, Lee HS, Choi JH, Lee SH, Paik WH, Ryu JK, Kim YT, Bang S, Lee ES. Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial. Ther Adv Med Oncol 2021;13:17588359211056179. [PMID: 34790261 DOI: 10.1177/17588359211056179] [Reference Citation Analysis]
293 Zhu Y, Zhang C, Zhao D, Li W, Zhao Z, Yao S, Zhao D. BDNF Acts as a Prognostic Factor Associated with Tumor-Infiltrating Th2 Cells in Pancreatic Adenocarcinoma. Dis Markers 2021;2021:7842035. [PMID: 34777634 DOI: 10.1155/2021/7842035] [Reference Citation Analysis]
294 Shi B, Chu J, Huang T, Wang X, Li Q, Gao Q, Xia Q, Luo S. The Scavenger Receptor MARCO Expressed by Tumor-Associated Macrophages Are Highly Associated With Poor Pancreatic Cancer Prognosis. Front Oncol 2021;11:771488. [PMID: 34778091 DOI: 10.3389/fonc.2021.771488] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
295 Asgharian P, Tazehkand AP, Soofiyani SR, Hosseini K, Martorell M, Tarhriz V, Ahangari H, Cruz-Martins N, Sharifi-Rad J, Almarhoon ZM, Ydyrys A, Nurzhanyat A, Yessenbekova A, Cho WC. Quercetin Impact in Pancreatic Cancer: An Overview on Its Therapeutic Effects. Oxid Med Cell Longev 2021;2021:4393266. [PMID: 34777687 DOI: 10.1155/2021/4393266] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
296 Torres MB, Dixon MEB, Gusani NJ. Undertreatment of Pancreatic Cancer: The Intersection of Bias, Biology, and Geography. Surg Oncol Clin N Am 2022;31:43-54. [PMID: 34776063 DOI: 10.1016/j.soc.2021.07.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
297 Stubbe BE, Henriksen SD, Madsen PH, Larsen AC, Krarup HB, Pedersen IS, Johansen MN, Thorlacius-Ussing O. Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma. Cancers (Basel) 2021;13:5717. [PMID: 34830873 DOI: 10.3390/cancers13225717] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
298 Xiong G, Pan S, Jin J, Wang X, He R, Peng F, Li X, Wang M, Zheng J, Zhu F, Qin R. Long Noncoding Competing Endogenous RNA Networks in Pancreatic Cancer. Front Oncol 2021;11:765216. [PMID: 34760707 DOI: 10.3389/fonc.2021.765216] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
299 Adachi K, Sakurai Y, Ichinoe M, Tadehara M, Tamaki A, Kesen Y, Kato T, Mii S, Enomoto A, Takahashi M, Koizumi W, Murakumo Y. CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer. Virchows Arch 2021. [PMID: 34762199 DOI: 10.1007/s00428-021-03230-2] [Reference Citation Analysis]
300 Hata T, Mizuma M, Motoi F, Ishida M, Ohtsuka H, Nakagawa K, Morikawa T, Furukawa T, Unno M. Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese population. Ann Gastroenterol Surg 2021;5:853-64. [PMID: 34755017 DOI: 10.1002/ags3.12482] [Reference Citation Analysis]
301 Kang MJ, Kim SW. Current status and perspectives of the future of pancreatic surgery: Establishment of evidence by integration of "art" and "science". Ann Gastroenterol Surg 2021;5:738-46. [PMID: 34755005 DOI: 10.1002/ags3.12494] [Reference Citation Analysis]
302 Wójcik B, Sawosz E, Szczepaniak J, Strojny B, Sosnowska M, Daniluk K, Zielińska-Górska M, Bałaban J, Chwalibog A, Wierzbicki M. Effects of Metallic and Carbon-Based Nanomaterials on Human Pancreatic Cancer Cell Lines AsPC-1 and BxPC-3. Int J Mol Sci 2021;22:12100. [PMID: 34829982 DOI: 10.3390/ijms222212100] [Reference Citation Analysis]
303 Ali I, Ahmed SBM, Elhaj BM, Ali HS, Alsubaie A, Almalki ASA. Enhanced anticancer activities of curcumin-loaded green gum acacia-based silver nanoparticles against melanoma and breast cancer cells. Appl Nanosci 2021;11:2679-87. [DOI: 10.1007/s13204-021-02176-w] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
304 Lei C, Hou Y, Chen J. Specificity protein 1-activated bone marrow stromal cell antigen 2 accelerates pancreatic cancer cell proliferation and migration. Exp Ther Med 2021;22:1459. [PMID: 34737799 DOI: 10.3892/etm.2021.10894] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
305 Huang R, Yang L, Zhang Z, Liu X, Fei Y, Tong WM, Niu Y, Liang Z. RNA m6A Demethylase ALKBH5 Protects Against Pancreatic Ductal Adenocarcinoma via Targeting Regulators of Iron Metabolism. Front Cell Dev Biol 2021;9:724282. [PMID: 34733841 DOI: 10.3389/fcell.2021.724282] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
306 Petenyi FG, Garay T, Muhl D, Izso B, Karaszi A, Borbenyi E, Herold M, Herold Z, Szasz AM, Dank M. Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients-A Single-Center Case-Control Study. Diseases 2021;9:81. [PMID: 34842668 DOI: 10.3390/diseases9040081] [Reference Citation Analysis]
307 Feng L, Wang J, Zhang J, Diao J, He L, Fu C, Liao H, Xu X, Gao Y, Zhou C. Comprehensive Analysis of E3 Ubiquitin Ligases Reveals Ring Finger Protein 223 as a Novel Oncogene Activated by KLF4 in Pancreatic Cancer. Front Cell Dev Biol 2021;9:738709. [PMID: 34722520 DOI: 10.3389/fcell.2021.738709] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
308 Xu Q, Chen S, Hu Y, Huang W. Clinical M2 macrophages-related genes to aid therapy in pancreatic ductal adenocarcinoma. Cancer Cell Int 2021;21:582. [PMID: 34717651 DOI: 10.1186/s12935-021-02289-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
309 Lim SA, Hao SB, Boyd BA, Mitsakos A, Irish W, Burke AM, Parikh AA, Snyder RA. Opportunity Costs of Surgical Resection and Perioperative Chemotherapy for Locoregional Pancreatic Adenocarcinoma. JCO Oncol Pract 2021;:OP2100311. [PMID: 34709961 DOI: 10.1200/OP.21.00311] [Reference Citation Analysis]
310 Sun CY. Current status of immunotherapy for pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2021; 29(20): 1151-1157 [DOI: 10.11569/wcjd.v29.i20.1151] [Reference Citation Analysis]
311 Kim A, Ha J, Kim J, Cho Y, Ahn J, Cheon C, Kim SH, Ko SG, Kim B. Natural Products for Pancreatic Cancer Treatment: From Traditional Medicine to Modern Drug Discovery. Nutrients 2021;13:3801. [PMID: 34836055 DOI: 10.3390/nu13113801] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
312 Chen D, Huang H, Zang L, Gao W, Zhu H, Yu X. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma. Front Immunol 2021;12:728062. [PMID: 34691034 DOI: 10.3389/fimmu.2021.728062] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
313 Marques HS, de Brito BB, da Silva FAF, Santos MLC, de Souza JCB, Correia TML, Lopes LW, Neres NSM, Dórea RSDM, Dantas ACS, Morbeck LLB, Lima IS, de Almeida AA, Dias MRJ, de Melo FF. Relationship between Th17 immune response and cancer. World J Clin Oncol 2021; 12(10): 845-867 [PMID: 34733609 DOI: 10.5306/wjco.v12.i10.845] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
314 Liu T, Li Q, Zhang W, Zhu Q. Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review. Front Oncol 2021;11:733955. [PMID: 34676166 DOI: 10.3389/fonc.2021.733955] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
315 Kovoor JG, Ma N, Tivey DR, Vandepeer M, Jacobsen JHW, Scarfe A, Vreugdenburg TD, Stretton B, Edwards S, Babidge WJ, Anthony AA, Padbury RTA, Maddern GJ. In-hospital survival after pancreatoduodenectomy is greater in high-volume hospitals versus lower-volume hospitals: a meta-analysis. ANZ J Surg 2021. [PMID: 34676647 DOI: 10.1111/ans.17293] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
316 Huang XY, Qin WT, Su QS, Qiu CC, Liu RC, Xie SS, Hu Y, Zhu SY. A New Stemness-Related Prognostic Model for Predicting the Prognosis in Pancreatic Ductal Adenocarcinoma. Biomed Res Int 2021;2021:6669570. [PMID: 34671679 DOI: 10.1155/2021/6669570] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
317 Qin T, Li J, Xiao Y, Wang X, Gong M, Wang Q, Zhu Z, Zhang S, Zhang W, Cao F, Han L, Wang Z, Ma Q, Sha H. Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling. Front Oncol 2021;11:728583. [PMID: 34671554 DOI: 10.3389/fonc.2021.728583] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
318 Zhu X, Zhang Y, Wang Y, Zhang H, Wang X, Tang H, Huang H, Zhou Z, Chen B, Sun L. Agrimoniin sensitizes pancreatic cancer to apoptosis through ROS-mediated energy metabolism dysfunction. Phytomedicine 2021;:153807. [PMID: 34785107 DOI: 10.1016/j.phymed.2021.153807] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
319 Zou W, Li L, Wang Z, Jiang N, Wang F, Hu M, Liu R. Up-regulation of S100P predicts the poor long-term survival and construction of prognostic signature for survival and immunotherapy in patients with pancreatic cancer. Bioengineered 2021;12:9006-20. [PMID: 34654352 DOI: 10.1080/21655979.2021.1992331] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
320 Schmittgen TD, Sempere LF. Acinar Cell-Enriched-MicroRNA-802 Connects the Dots Between Kras Signaling, Acinar Ductal Metaplasia, and Pancreatic Cancer. Gastroenterology 2021:S0016-5085(21)03645-3. [PMID: 34662582 DOI: 10.1053/j.gastro.2021.10.011] [Reference Citation Analysis]
321 Luo D, Liu Y, Li Z, Zhu H, Yu X. NR2F1-AS1 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Competing Endogenous RNA Regulatory Network Constructed by Sponging miRNA-146a-5p/miRNA-877-5p. Front Cell Dev Biol 2021;9:736980. [PMID: 34650983 DOI: 10.3389/fcell.2021.736980] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
322 Pekarek L, Fraile-Martinez O, Garcia-Montero C, Alvarez-Mon MA, Acero J, Ruiz-Llorente L, García-Honduvilla N, Albillos A, Buján J, Alvarez-Mon M, Guijarro LG, Ortega MA. Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives. Oncol Lett 2021;22:809. [PMID: 34630716 DOI: 10.3892/ol.2021.13070] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
323 Xing J, Yang B, Hou X, Jia N, Gong X, Li X, Zhou N, Cheng Y, Bai C. Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resection. Front Oncol 2021;11:660215. [PMID: 34631515 DOI: 10.3389/fonc.2021.660215] [Reference Citation Analysis]
324 Sun M, Xie M, Zhang T, Wang Y, Huang W, Xia L. m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Pancreatic Cancer. Front Immunol 2021;12:739768. [PMID: 34616403 DOI: 10.3389/fimmu.2021.739768] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
325 Qiu G, Zhang L, Gu Z, Ren H, Du Y, Li Z, Wang C. Preoperative Alkaline Phosphatase-to-Cholesterol Ratio as a Predictor of Overall Survival in Pancreatic Ductal Adenocarcinoma Patients Undergoing Radical Pancreaticoduodenectomy. Med Sci Monit 2021;27:e931868. [PMID: 34599137 DOI: 10.12659/MSM.931868] [Reference Citation Analysis]
326 Barbagallo M, Ciprani D, Rimassa L, Cortese N, Comito T, Spaggiari P, Marchesi F, Zerbi A. The Immune Landscape in a Long-Term Survival Pancreatic Adenocarcinoma Patient Highly Responsive to a Multidisciplinary Approach With Chemo-Radio Treatments. Pancreas 2021;50:e76-8. [PMID: 34860821 DOI: 10.1097/MPA.0000000000001907] [Reference Citation Analysis]
327 Kisling SG, Natarajan G, Pothuraju R, Shah A, Batra SK, Kaur S. Implications of prognosis-associated genes in pancreatic tumor metastasis: lessons from global studies in bioinformatics. Cancer Metastasis Rev 2021;40:721-38. [PMID: 34591244 DOI: 10.1007/s10555-021-09991-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
328 Sempere LF, Powell K, Rana J, Brock AA, Schmittgen TD. Role of non-coding RNAs in tumor progression and metastasis in pancreatic cancer. Cancer Metastasis Rev 2021;40:761-76. [PMID: 34591242 DOI: 10.1007/s10555-021-09995-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
329 Palacios-Acedo AL, Mezouar S, Mège D, Crescence L, Dubois C, Panicot-Dubois L. P2RY12-Inhibitors Reduce Cancer-Associated Thrombosis and Tumor Growth in Pancreatic Cancers. Front Oncol 2021;11:704945. [PMID: 34589424 DOI: 10.3389/fonc.2021.704945] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
330 de Jesus VHF, Riechelmann RP. Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis. Ecancermedicalscience 2021;15:1276. [PMID: 34567261 DOI: 10.3332/ecancer.2021.1276] [Reference Citation Analysis]
331 Xu PL, Cheng CS, Jiao JY, Chen H, Chen Z, Li P. Matrine injection inhibits pancreatic cancer growth via modulating carbonic anhydrases- a network pharmacology-based study with in vitro validation. J Ethnopharmacol 2021;:114691. [PMID: 34597654 DOI: 10.1016/j.jep.2021.114691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
332 Mojtahedi Z, Yoo JW, Callahan K, Bhandari N, Lou D, Ghodsi K, Shen JJ. Inpatient Palliative Care Is Less Utilized in Rare, Fatal Extrahepatic Cholangiocarcinoma: A Ten-Year National Perspective. Int J Environ Res Public Health 2021;18:10004. [PMID: 34639305 DOI: 10.3390/ijerph181910004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
333 Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. World J Gastroenterol 2021;27:5851-89. [PMID: 34629806 DOI: 10.3748/wjg.v27.i35.5851] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
334 Hashimoto K, Inada M, Yamamoto Y, Ochiya T. Preliminary evaluation of miR-1307-3p in human serum for detection of 13 types of solid cancer using microRNA chip. Heliyon 2021;7:e07919. [PMID: 34541347 DOI: 10.1016/j.heliyon.2021.e07919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
335 Chong E, Ratnayake B, Dasari BVM, Loveday BPT, Siriwardena AK, Pandanaboyana S. Adjuvant Chemotherapy in the Treatment of Intraductal Papillary Mucinous Neoplasms of the Pancreas: Systematic Review and Meta-Analysis. World J Surg 2021. [PMID: 34545418 DOI: 10.1007/s00268-021-06309-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
336 Yu L, Xie X, Cao X, Chen J, Chen G, Chen Y, Li G, Qin J, Peng F, Peng C. The Anticancer Potential of Maslinic Acid and Its Derivatives: A Review. Drug Des Devel Ther 2021;15:3863-79. [PMID: 34526766 DOI: 10.2147/DDDT.S326328] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
337 Herold Z, Szasz AM, Dank M. Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system. World J Gastrointest Oncol 2021;13:1109-20. [PMID: 34616516 DOI: 10.4251/wjgo.v13.i9.1109] [Reference Citation Analysis]
338 Heo SH, Jang SI, Kim SY, Choi B, Lee DK, Lee HK, Chang EJ. Characterization of Circulating IL-7R Positive Cell Populations for Early Detection of Pancreatic Ductal Adenocarcinoma. J Clin Med 2021;10:4157. [PMID: 34575268 DOI: 10.3390/jcm10184157] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
339 Tang S, Huang X, Jiang H, Qin S. Identification of a Five-Gene Prognostic Signature Related to B Cells Infiltration in Pancreatic Adenocarcinoma. Int J Gen Med 2021;14:5051-68. [PMID: 34511988 DOI: 10.2147/IJGM.S324432] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
340 Wang K, Miao X, Kong F, Huang S, Mo J, Jin C, Zheng Y. Integrating Network Pharmacology and Experimental Verification to Explore the Mechanism of Effect of Zuojin Pills in Pancreatic Cancer Treatment. Drug Des Devel Ther 2021;15:3749-64. [PMID: 34511884 DOI: 10.2147/DDDT.S323360] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
341 Murase Y, Ono H, Ogawa K, Yoshioka R, Ishikawa Y, Ueda H, Akahoshi K, Ban D, Kudo A, Tanaka S, Tanabe M. Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers. Cancer Sci 2021;112:4641-54. [PMID: 34510663 DOI: 10.1111/cas.15134] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
342 Wang J, Chen Y, Li X, Zou X. Perineural Invasion and Associated Pain Transmission in Pancreatic Cancer. Cancers (Basel) 2021;13:4594. [PMID: 34572820 DOI: 10.3390/cancers13184594] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
343 Wang X, Hu L, Yang X, Chen F, Xu H, Yu H, Song Z, Fei J, Zhong Z. Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy. Exp Ther Med 2021;22:1140. [PMID: 34504586 DOI: 10.3892/etm.2021.10574] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
344 Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M. Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. Oncologist 2021;26:e1982-91. [PMID: 34506673 DOI: 10.1002/onco.13968] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
345 Luo D, Xu X, Iqbal MZ, Zhao Q, Zhao R, Farheen J, Zhang Q, Zhang P, Kong X. siRNA-Loaded Hydroxyapatite Nanoparticles for KRAS Gene Silencing in Anti-Pancreatic Cancer Therapy. Pharmaceutics 2021;13:1428. [PMID: 34575504 DOI: 10.3390/pharmaceutics13091428] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
346 Duan X, Wang W, Pan Q, Guo L. Type 2 Diabetes Mellitus Intersects With Pancreatic Cancer Diagnosis and Development. Front Oncol 2021;11:730038. [PMID: 34485159 DOI: 10.3389/fonc.2021.730038] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
347 Wang G, Dai S, Gao H, Gao Y, Yin L, Zhang K, Huang X, Lu Z, Miao Y. Opposite Roles of Tumor Cell Proliferation and Immune Cell Infiltration in Postoperative Liver Metastasis of PDAC. Front Cell Dev Biol 2021;9:714718. [PMID: 34485300 DOI: 10.3389/fcell.2021.714718] [Reference Citation Analysis]
348 McCraw AJ, Chauhan J, Bax HJ, Stavraka C, Osborn G, Grandits M, López-Abente J, Josephs DH, Spicer J, Wagner GK, Karagiannis SN, Chenoweth A, Crescioli S. Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments. Cancers (Basel) 2021;13:4460. [PMID: 34503270 DOI: 10.3390/cancers13174460] [Reference Citation Analysis]
349 Gupta A, Khalid O, Moravek C, Lamkin A, Matrisian LM, Doss S, Denlinger CS, Coveler AL, Weekes CD, Roeland EJ, Hendifar AE, Nipp RD. Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience. Cancer Med 2021;10:7152-61. [PMID: 34477302 DOI: 10.1002/cam4.4257] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
350 Li E, Huang X, Zhang G, Liang T. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. J Exp Clin Cancer Res 2021;40:279. [PMID: 34479614 DOI: 10.1186/s13046-021-02055-w] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
351 Karimnia V, Slack FJ, Celli JP. Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:4354. [PMID: 34503165 DOI: 10.3390/cancers13174354] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
352 Zhang Q, Lu J, Jia M, Ma Y, Sun M, Chen X, Ma X, Yang Y, Kang J, Zhang X, Paiella S, Katz MHG, Tsuchida K, Schattner M, Du S. Evaluation of the reporting quality of clinical practice guidelines on pancreatic cancer using the RIGHT checklist. Ann Transl Med 2021;9:1088. [PMID: 34423000 DOI: 10.21037/atm-21-2644] [Reference Citation Analysis]
353 Yang T, Shen P, Chen Q, Wu P, Yuan H, Ge W, Meng L, Huang X, Fu Y, Zhang Y, Hu W, Miao Y, Lu Z, Jiang K. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res 2021;40:261. [PMID: 34416910 DOI: 10.1186/s13046-021-02063-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
354 Burkhardt C, Bühler L, Viertl D, Stora T. New Isotopes for the Treatment of Pancreatic Cancer in Collaboration With CERN: A Mini Review. Front Med (Lausanne) 2021;8:674656. [PMID: 34409048 DOI: 10.3389/fmed.2021.674656] [Reference Citation Analysis]
355 Acier A, Godard M, Gassiot F, Finetti P, Rubis M, Nowak J, Bertucci F, Iovanna JL, Tomasini R, Lécorché P, Jacquot G, Khrestchatisky M, Temsamani J, Malicet C, Vasseur S, Guillaumond F. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma. Commun Biol 2021;4:987. [PMID: 34413441 DOI: 10.1038/s42003-021-02508-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
356 Roy A, Sahoo J, Kamalanathan S, Naik D, Mohan P, Kalayarasan R. Diabetes and pancreatic cancer: Exploring the two-way traffic. World J Gastroenterol 2021;27:4939-62. [PMID: 34497428 DOI: 10.3748/wjg.v27.i30.4939] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
357 Fatima I, Barman S, Uppada J, Chauhan S, Rauth S, Rachagani S, Ponnusamy MP, Smith L, Talmon G, Singh AB, Batra SK, Dhawan P. MASTL regulates EGFR signaling to impact pancreatic cancer progression. Oncogene 2021. [PMID: 34331012 DOI: 10.1038/s41388-021-01951-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
358 Huang W, Hua H, Xiao G, Yang X, Yang Q, Jin L. ZC3HAV1 promotes the proliferation and metastasis via regulating KRAS in pancreatic cancer. Aging (Albany NY) 2021;13:18482-97. [PMID: 34319912 DOI: 10.18632/aging.203296] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
359 Zhang Z, Qin Y, Ji S, Xu W, Liu M, Hu Q, Ye Z, Fan G, Yu X, Liu W, Xu X. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. Acta Biochim Biophys Sin (Shanghai) 2021;53:997-1008. [PMID: 34117747 DOI: 10.1093/abbs/gmab074] [Reference Citation Analysis]
360 Yagyu T, Ohira T, Shimizu R, Morimoto M, Murakami Y, Hanaki T, Kihara K, Matsunaga T, Yamamoto M, Tokuyasu N, Sakamoto T, Fujiwara Y, Kugoh H. Human chromosome 3p21.3 carries TERT transcriptional regulators in pancreatic cancer. Sci Rep 2021;11:15355. [PMID: 34321527 DOI: 10.1038/s41598-021-94711-6] [Reference Citation Analysis]
361 Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, Zhang G, Guo C, Zhang X, Chen W, Yadav DK, Bai X, Liang T. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun 2021;12:4536. [PMID: 34315872 DOI: 10.1038/s41467-021-24769-3] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
362 Stasiewicz M, Kwaśniewski M, Karpiński TM. Microbial Associations with Pancreatic Cancer: A New Frontier in Biomarkers. Cancers (Basel) 2021;13:3784. [PMID: 34359685 DOI: 10.3390/cancers13153784] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
363 Zhang B, Hu Q, Yu J, Wang J, Yang H, Lou J, Cai G, Huang H, Xu M, Xiao Z, Zhang Y. Heterochronous Metastases of Lung Adenocarcinoma to Pancreas and Liver: A Case Report from Pathological Perspectives. Onco Targets Ther 2021;14:4269-73. [PMID: 34326648 DOI: 10.2147/OTT.S314385] [Reference Citation Analysis]
364 Ding Q, Sun Y, Shang J, Li F, Zhang Y, Liu JX. NMFNA: A Non-negative Matrix Factorization Network Analysis Method for Identifying Modules and Characteristic Genes of Pancreatic Cancer. Front Genet 2021;12:678642. [PMID: 34367241 DOI: 10.3389/fgene.2021.678642] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
365 Hamad A, Brown ZJ, Ejaz AM, Dillhoff M, Cloyd JM. Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care. World J Gastroenterol 2021; 27(27): 4383-4394 [PMID: 34366611 DOI: 10.3748/wjg.v27.i27.4383] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
366 Hu J, Zheng Z, Lei J, Cao Y, Li Q, Zheng Z, Chen C. Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer. PPAR Res 2021;2021:5589342. [PMID: 34335707 DOI: 10.1155/2021/5589342] [Reference Citation Analysis]
367 Gardouh AR, Srag El-Din ASG, Salem MSH, Moustafa Y, Gad S. Starch Nanoparticles for Enhancement of Oral Bioavailability of a Newly Synthesized Thienopyrimidine Derivative with Anti-Proliferative Activity Against Pancreatic Cancer. Drug Des Devel Ther 2021;15:3071-93. [PMID: 34305395 DOI: 10.2147/DDDT.S321962] [Reference Citation Analysis]
368 Li R, He Y, Zhang H, Wang J, Liu X, Liu H, Wu H, Liang Z. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy. Front Immunol 2021;12:690056. [PMID: 34335594 DOI: 10.3389/fimmu.2021.690056] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
369 Cao J, Sun Y, Zhang C, Wang X, Zeng Y, Zhang T, Huang P. Tablet-like TiO2/C nanocomposites for repeated type I sonodynamic therapy of pancreatic cancer. Acta Biomater 2021;129:269-79. [PMID: 34082101 DOI: 10.1016/j.actbio.2021.05.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
370 Zhao Z, Zhao G, Yang S, Zhu S, Zhang S, Li P. The significance of exosomal RNAs in the development, diagnosis, and treatment of pancreatic cancer. Cancer Cell Int 2021;21:364. [PMID: 34243775 DOI: 10.1186/s12935-021-02059-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
371 Wild J, Distelmeier S, Keil P, Weinmann A, Münzel T, Weinmann-Menke J, Kraus D. Non-bacterial thrombotic endocarditis in a patient with pancreatic carcinoma. Echocardiography 2021;38:1455-8. [PMID: 34231929 DOI: 10.1111/echo.15140] [Reference Citation Analysis]
372 Dong Y, Tian J, Yan B, Lv K, Li J, Fu D. Liver-Metastasis-Related Genes are Potential Biomarkers for Predicting the Clinical Outcomes of Patients with Pancreatic Adenocarcinoma. Pathol Oncol Res 2021;27:1609822. [PMID: 34290570 DOI: 10.3389/pore.2021.1609822] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
373 Wang S, Zheng Y, Yang F, Zhu L, Zhu XQ, Wang ZF, Wu XL, Zhou CH, Yan JY, Hu BY, Kong B, Fu DL, Bruns C, Zhao Y, Qin LX, Dong QZ. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther 2021;6:249. [PMID: 34219130 DOI: 10.1038/s41392-021-00659-4] [Cited by in F6Publishing: 22] [Reference Citation Analysis]
374 . Advancing on pancreatic cancer. Nat Rev Gastroenterol Hepatol 2021;18:447. [PMID: 34188210 DOI: 10.1038/s41575-021-00479-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
375 Fu H, Ni X, Ni F, Li D, Sun H, Kong H, Shan Y, Dai S. Study of the Mechanism by Which Curcumin Cooperates with Sestrin2 to Inhibit the Growth of Pancreatic Cancer. Gastroenterol Res Pract 2021;2021:7362233. [PMID: 34306067 DOI: 10.1155/2021/7362233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
376 Lodestijn SC, van Neerven SM, Vermeulen L, Bijlsma MF. Stem Cells in the Exocrine Pancreas during Homeostasis, Injury, and Cancer. Cancers (Basel) 2021;13:3295. [PMID: 34209288 DOI: 10.3390/cancers13133295] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
377 Qiu CJ, Wang XB, Zheng ZR, Yang CZ, Lin K, Zhang K, Tu M, Jiang KR, Gao WT. Development and validation of a ferroptosis-related prognostic model in pancreatic cancer. Invest New Drugs 2021. [PMID: 34195903 DOI: 10.1007/s10637-021-01114-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
378 Li ZY, Sun XY. Recent progress in SRC targeted therapy for pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2021; 29(12): 621-627 [DOI: 10.11569/wcjd.v29.i12.621] [Reference Citation Analysis]
379 Fu H, Mi W, Pan B, Guo Y, Li J, Xu R, Zheng J, Zou C, Zhang T, Liang Z, Zou J, Zou H. Automatic Pancreatic Ductal Adenocarcinoma Detection in Whole Slide Images Using Deep Convolutional Neural Networks. Front Oncol 2021;11:665929. [PMID: 34249702 DOI: 10.3389/fonc.2021.665929] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
380 Liu Q, Zhang J, Jiang M, Zhang Y, Chen T, Zhang J, Li B, Chen J, Xing W. Evaluating the Histopathology of Pancreatic Ductal Adenocarcinoma by Intravoxel Incoherent Motion-Diffusion Weighted Imaging Comparing With Diffusion-Weighted Imaging. Front Oncol 2021;11:670085. [PMID: 34249707 DOI: 10.3389/fonc.2021.670085] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
381 Lawlor RT, Mattiolo P, Mafficini A, Hong SM, Piredda ML, Taormina SV, Malleo G, Marchegiani G, Pea A, Salvia R, Kryklyva V, Shin JI, Brosens LA, Milella M, Scarpa A, Luchini C. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Cancers (Basel) 2021;13:3119. [PMID: 34206554 DOI: 10.3390/cancers13133119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
382 Kaushal JB, Bhatia R, Kanchan RK, Raut P, Mallapragada S, Ly QP, Batra SK, Rachagani S. Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β. Cancers (Basel) 2021;13:3105. [PMID: 34206370 DOI: 10.3390/cancers13133105] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
383 Granlund L, Hedin A, Wahlhütter M, Seiron P, Korsgren O, Skog O, Lundberg M. Histological and transcriptional characterization of the pancreatic acinar tissue in type 1 diabetes. BMJ Open Diabetes Res Care 2021;9:e002076. [PMID: 34031141 DOI: 10.1136/bmjdrc-2020-002076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
384 Zhang H, Qu M, Gorur A, Sun Z, Cata JP, Chen W, Miao C. Association of Mu-Opioid Receptor(MOR) Expression and Opioids Requirement With Survival in Patients With Stage I-III Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:686877. [PMID: 34222012 DOI: 10.3389/fonc.2021.686877] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
385 Zhou S, Zhu C, Chen SL, Li JA, Qu KL, Jing H, Wang Y, Pang Q, Liu HC. 125I Intracavitary Irradiation Combined with 125I Seeds Implantation for Treatment of Locally Advanced Pancreatic Head Cancer: A Retrospective Analysis of 67 Cases. Int J Gen Med 2021;14:2645-53. [PMID: 34177273 DOI: 10.2147/IJGM.S309069] [Reference Citation Analysis]
386 Ahmad RS, Eubank TD, Lukomski S, Boone BA. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer. Biomolecules 2021;11:901. [PMID: 34204306 DOI: 10.3390/biom11060901] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
387 Öman M, Wettergren Y, Odin E, Westermark S, Naredi P, Hemmingsson O, Taflin H. Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol 2021;88:619-31. [PMID: 34132895 DOI: 10.1007/s00280-021-04318-x] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
388 Zhang Y, Huang ZX, Song B. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma. World J Gastroenterol 2021; 27(22): 3037-3049 [PMID: 34168406 DOI: 10.3748/wjg.v27.i22.3037] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
389 Flak RV, Fisker RV, Bruun NH, Stender MT, Thorlacius-Ussing O, Petersen LJ. Usefulness of Imaging Response Assessment after Irreversible Electroporation of Localized Pancreatic Cancer-Results from a Prospective Cohort. Cancers (Basel) 2021;13:2862. [PMID: 34201272 DOI: 10.3390/cancers13122862] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
390 Chang WH, Nguyen TT, Hsu CH, Bryant KL, Kim HJ, Ying H, Erickson JW, Der CJ, Cerione RA, Antonyak MA. KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin. Cancer Lett 2021;517:66-77. [PMID: 34111513 DOI: 10.1016/j.canlet.2021.05.031] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
391 Bruno R, Sensi E, Lupi C, Giordano M, Bernardini L, Vivaldi C, Fornaro L, Vasile E, Campani D, Fontanini G. Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series. Diagnostics (Basel) 2021;11:1046. [PMID: 34200245 DOI: 10.3390/diagnostics11061046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
392 Luo H, Galvão DA, Newton RU, Tang C, Dean A, Jasas K, Johansson M, Yusoff I, Spry N, Taaffe DR. Feasibility and efficacy of a multicomponent exercise medicine programme in patients with pancreatic cancer undergoing neoadjuvant therapy (the EXPAN trial): study protocol of a dual-centre, two-armed phase I randomised controlled trial. BMJ Open Gastroenterol 2021;8:e000642. [PMID: 34099463 DOI: 10.1136/bmjgast-2021-000642] [Reference Citation Analysis]
393 Chen Y, Xu R, Ruze R, Yang J, Wang H, Song J, You L, Wang C, Zhao Y. Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. Cancer Cell Int 2021;21:291. [PMID: 34090418 DOI: 10.1186/s12935-021-01928-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
394 Sun H, Zhang D, Huang C, Guo Y, Yang Z, Yao N, Dong X, Cheng R, Zhao N, Meng J, Sun B, Hao J. Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer. Cancer Biol Med 2021:j. [PMID: 34086429 DOI: 10.20892/j.issn.2095-3941.2021.0158] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
395 Li J, Wang F, Liu Y, Wang H, Ni B. N6-methyladenosine (m6A) in pancreatic cancer: Regulatory mechanisms and future direction. Int J Biol Sci 2021;17:2323-35. [PMID: 34239358 DOI: 10.7150/ijbs.60115] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
396 Bhattacharjee S, Hamberger F, Ravichandra A, Miller M, Nair A, Affo S, Filliol A, Chin L, Savage TM, Yin D, Wirsik NM, Mehal A, Arpaia N, Seki E, Mack M, Zhu D, Sims PA, Kalluri R, Stanger BZ, Olive KP, Schmidt T, Wells RG, Mederacke I, Schwabe RF. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J Clin Invest 2021;131:146987. [PMID: 33905375 DOI: 10.1172/JCI146987] [Cited by in Crossref: 6] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
397 Brown ZJ, Cloyd JM. Surgery for pancreatic cancer: recent progress and future directions. Hepatobiliary Surg Nutr 2021;10:376-8. [PMID: 34159167 DOI: 10.21037/hbsn-21-18] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
398 Aoyama R, Hori T, Yamamoto H, Harada H, Yamamoto M, Yamada M, Yazawa T, Sasaki B, Tani M, Sato A, Katsura H, Kamada Y, Tani R, Sasaki Y, Zaima M. A Thought-Provoking Case of Successfully Treated Carcinoma of the Head of the Pancreas with Metachronous Lung Metastasis: Impact of Distal Spleno-Renal Shunt for Regional Invasion on Long-Term Period after Pancreaticoduodenectomy. Case Rep Surg 2021;2021:6689419. [PMID: 34136302 DOI: 10.1155/2021/6689419] [Reference Citation Analysis]
399 Coppola A, La Vaccara V, Fiore M, Farolfi T, Ramella S, Angeletti S, Coppola R, Caputo D. CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. Front Oncol 2021;11:690580. [PMID: 34123859 DOI: 10.3389/fonc.2021.690580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
400 Ji X, Zhao Y, He C, Han S, Zhu X, Shen Z, Chen C, Chu X. Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer. Front Oncol 2021;11:659987. [PMID: 34123818 DOI: 10.3389/fonc.2021.659987] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
401 Lin X, Lin R, Lu F, Yang Y, Wang C, Fang H, Chen Y, Huang H. Laparoscopic biopsy and staging for locally advanced pancreatic cancer: experiences of 76 consecutive patients in a single institution. Langenbecks Arch Surg 2021. [PMID: 34021414 DOI: 10.1007/s00423-021-02199-5] [Reference Citation Analysis]
402 Kriegsmann M, Kriegsmann K, Steinbuss G, Zgorzelski C, Kraft A, Gaida MM. Deep Learning in Pancreatic Tissue: Identification of Anatomical Structures, Pancreatic Intraepithelial Neoplasia, and Ductal Adenocarcinoma. Int J Mol Sci 2021;22:5385. [PMID: 34065423 DOI: 10.3390/ijms22105385] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
403 Zhang Z, Zhang H, Yang H, Xu Z. Heptaphylline inhibits the proliferation and epithelial to mesenchymal transition of human pancreatic cancer cells via induction of apoptosis and autophagy. All Life 2021;14:484-91. [DOI: 10.1080/26895293.2021.1925357] [Reference Citation Analysis]
404 Hoare O, Fraunhoffer N, Elkaoutari A, Gayet O, Bigonnet M, Roques J, Nicolle R, McGuckin C, Forraz N, Sohier E, Tonon L, Wajda P, Boyault S, Attignon V, Tabone-Eglinger S, Barbier S, Mignard C, Duchamp O, Iovanna J, Dusetti NJ. Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. Cancers (Basel) 2021;13:2473. [PMID: 34069519 DOI: 10.3390/cancers13102473] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
405 Gao C, Quan MY, Chen QJ, Yang R, Wu Y, Liu JY, Lin ZY, Li X, Cai JT, Jiang TF, Xu L, Mossahebi-Mohammadi M, Guo Q, Zhang JS. Yap1-2 Isoform Is the Primary Mediator in TGF-β1 Induced EMT in Pancreatic Cancer. Front Oncol 2021;11:649290. [PMID: 34094936 DOI: 10.3389/fonc.2021.649290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
406 Zou W, Wang Z, Wang F, Zhang G, Liu R. A nomogram predicting overall survival in patients with non-metastatic pancreatic head adenocarcinoma after surgery: a population-based study. BMC Cancer 2021;21:524. [PMID: 33964898 DOI: 10.1186/s12885-021-08250-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
407 Yoon JH, Jung YJ, Moon SH. Immunotherapy for pancreatic cancer. World J Clin Cases 2021; 9(13): 2969-2982 [PMID: 33969083 DOI: 10.12998/wjcc.v9.i13.2969] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
408 Feng Z, Li K, Lou J, Wu Y, Peng C. An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma. Front Cell Dev Biol 2021;9:665161. [PMID: 33996821 DOI: 10.3389/fcell.2021.665161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
409 Geerdes EE, Sideras K, Aziz MH, van Eijck CH, Bruno MJ, Sprengers D, Boor PPC, Kwekkeboom J. Cancer Cell B7-H3 Expression Is More Prevalent in the Pancreato-Biliary Subtype of Ampullary Cancer Than in Pancreatic Cancer. Front Oncol 2021;11:615691. [PMID: 33996541 DOI: 10.3389/fonc.2021.615691] [Reference Citation Analysis]
410 Peng C, Xu B, Xiao J, Zhou C, Li X, Shi H, Qiang W, Wang T, Zhao J, Liu F, Li G, Li H, Chen C, Shi L. Hepatic Artery Infusion of Floxuridine in Combination With Systemic Chemotherapy for Pancreatic Cancer Liver Metastasis: A Propensity Score-Matched Analysis in Two Centers. Front Oncol 2021;11:652426. [PMID: 33996572 DOI: 10.3389/fonc.2021.652426] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
411 Gu ZT, Li ZZ, Wang CF. Advances in research of extracellular mechanisms underlying gemcitabine resistance in pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2021; 29(8): 421-434 [DOI: 10.11569/wcjd.v29.i8.421] [Reference Citation Analysis]
412 Sharvit L, Bar-Shalom R, Azzam N, Yechiel Y, Wasser S, Fares F. Cyathus striatus Extract Induces Apoptosis in Human Pancreatic Cancer Cells and Inhibits Xenograft Tumor Growth In Vivo. Cancers (Basel) 2021;13:2017. [PMID: 33922003 DOI: 10.3390/cancers13092017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
413 Heredia-Soto V, Rodríguez-Salas N, Feliu J. Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice? Cancers (Basel) 2021;13:1986. [PMID: 33924143 DOI: 10.3390/cancers13081986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
414 Aoki MN, Stein A, de Oliveira JC, Chammas R, Uno M, Munhoz FBA, Marin AM, Canzian F. Susceptibility loci for pancreatic cancer in the Brazilian population. BMC Med Genomics 2021;14:111. [PMID: 33879152 DOI: 10.1186/s12920-021-00956-5] [Reference Citation Analysis]
415 Zhou Y, Zhu Y, Dong X, Cao G, Li Y, Fan Y, Chen Q, Cai H, Wu Y. Exosomes Derived from Pancreatic Cancer Cells Induce Osteoclast Differentiation Through the miR125a-5p/TNFRSF1B Pathway. Onco Targets Ther 2021;14:2727-39. [PMID: 33907416 DOI: 10.2147/OTT.S282319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
416 Li X, Lin P, Tao Y, Jiang X, Li T, Wang Y, Wang C, Cao Y. LECT 2 Antagonizes FOXM1 Signaling via Inhibiting MET to Retard PDAC Progression. Front Cell Dev Biol 2021;9:661122. [PMID: 33937262 DOI: 10.3389/fcell.2021.661122] [Reference Citation Analysis]
417 Monroy-Iglesias MJ, Dolly S, Sarker D, Thillai K, Van Hemelrijck M, Santaolalla A. Pancreatic Cancer Exposome Profile to Aid Early Detection and Inform Prevention Strategies. J Clin Med 2021;10:1665. [PMID: 33924591 DOI: 10.3390/jcm10081665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
418 Rai ZL, Feakins R, Pallett LJ, Manas D, Davidson BR. Irreversible Electroporation (IRE) in Locally Advanced Pancreatic Cancer: A Review of Current Clinical Outcomes, Mechanism of Action and Opportunities for Synergistic Therapy. J Clin Med 2021;10:1609. [PMID: 33920118 DOI: 10.3390/jcm10081609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
419 Zhou X, Liu K, Cui J, Xiong J, Wu H, Peng T, Guo Y. Circ-MBOAT2 knockdown represses tumor progression and glutamine catabolism by miR-433-3p/GOT1 axis in pancreatic cancer. J Exp Clin Cancer Res 2021;40:124. [PMID: 33832516 DOI: 10.1186/s13046-021-01894-x] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
420 Gentiluomo M, Corradi C, Vanella G, Johansen AZ, Strobel O, Szentesi A, Milanetto AC, Hegyi P, Kupcinskas J, Tavano F, Neoptolemos JP, Bozzato D, Hackert T, Pezzilli R, Johansen JS, Costello E, Mohelnikova-Duchonova B, van Eijck CHJ, Talar-Wojnarowska R, Hansen CP, Darvasi E, Chen IM, Cavestro GM, Soucek P, Piredda L, Vodicka P, Gazouli M, Arcidiacono PG, Canzian F, Campa D, Capurso G. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Sci Rep 2021;11:7570. [PMID: 33828170 DOI: 10.1038/s41598-021-87130-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
421 Jiang P, Yang F, Zou C, Bao T, Wu M, Yang D, Bu S. The construction and analysis of a ferroptosis-related gene prognostic signature for pancreatic cancer. Aging (Albany NY) 2021;13:10396-414. [PMID: 33819918 DOI: 10.18632/aging.202801] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
422 Shinzawa K, Kageta D, Nash RJ, Fleet GW, Imahori T, Kato A. Azobenzene derivatives show anti-cancer activity against pancreatic cancer cells only under nutrient starvation conditions via G0/G1 cell cycle arrest. Tetrahedron 2021;85:132077. [DOI: 10.1016/j.tet.2021.132077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
423 Taguchi K, Okamoto Y, Matsumoto K, Otagiri M, Chuang VTG. When Albumin Meets Liposomes: A Feasible Drug Carrier for Biomedical Applications. Pharmaceuticals (Basel) 2021;14:296. [PMID: 33810483 DOI: 10.3390/ph14040296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
424 Tang N, Xu S, Song T, Qiu Y, He J, Fu X. Zinc finger protein 91 accelerates tumour progression by activating β-catenin signalling in pancreatic cancer. Cell Prolif 2021;54:e13031. [PMID: 33755268 DOI: 10.1111/cpr.13031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
425 Shen P, Yang T, Chen Q, Yuan H, Wu P, Cai B, Meng L, Huang X, Liu J, Zhang Y, Hu W, Miao Y, Lu Z, Jiang K. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Mol Cancer 2021;20:51. [PMID: 33750389 DOI: 10.1186/s12943-021-01333-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
426 De Lellis L, Florio R, Di Bella MC, Brocco D, Guidotti F, Tinari N, Grassadonia A, Lattanzio R, Cama A, Veschi S. Exosomes as Pleiotropic Players in Pancreatic Cancer. Biomedicines 2021;9:275. [PMID: 33803470 DOI: 10.3390/biomedicines9030275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
427 Li MX, Wang HY, Yuan CH, Ma ZL, Jiang B, Li L, Zhang L, Xiu DR. Establishment of a Macrophage Phenotypic Switch Related Prognostic Signature in Patients With Pancreatic Cancer. Front Oncol 2021;11:619517. [PMID: 33747931 DOI: 10.3389/fonc.2021.619517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
428 Heinzman Z, Schmidt C, Sliwinski MK, Goonesekere NCW. The Case for GNMT as a Biomarker and a Therapeutic Target in Pancreatic Cancer. Pharmaceuticals (Basel) 2021;14:209. [PMID: 33802396 DOI: 10.3390/ph14030209] [Reference Citation Analysis]
429 Mataki Y, Kurahara H, Idichi T, Tanoue K, Hozaka Y, Kawasaki Y, Iino S, Maemura K, Shinchi H, Ohtsuka T. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis. Cancers (Basel) 2021;13:1057. [PMID: 33801465 DOI: 10.3390/cancers13051057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
430 Ma Z, Zhou Z, Zhuang H, Li Z, Ma Z, Huang B, Liu C, Gong Y, Zou Y, Zheng Z, Huang S, Zhang C, Hou B. Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. Dis Markers 2021;2021:6682697. [PMID: 33747255 DOI: 10.1155/2021/6682697] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
431 Su W, Zhu S, Chen K, Yang H, Tian M, Fu Q, Shi G, Feng S, Ren D, Jin X, Yang C. Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer. J Exp Clin Cancer Res 2021;40:88. [PMID: 33648545 DOI: 10.1186/s13046-021-01879-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
432 Xu H, Hua J, Meng Q, Wang X, Xu J, Wang W, Zhang B, Liu J, Liang C, Yu X, Shi S. Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape. Front Oncol 2021;11:640820. [PMID: 33718237 DOI: 10.3389/fonc.2021.640820] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
433 Tonelli C, Ringhouse B, Bunn C, Luchette F. The Impact of the Aging Population on Surgical Diseases. Curr Geri Rep 2021;10:21-31. [DOI: 10.1007/s13670-020-00352-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
434 Tu J, Huang Z, Wang Y, Wang M, Yin Z, Mei X, Li M, Li L. Transcriptome analysis of the procession from chronic pancreatitis to pancreatic cancer and metastatic pancreatic cancer. Sci Rep 2021;11:3409. [PMID: 33564087 DOI: 10.1038/s41598-021-83015-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
435 Sun F, Zhu Q, Li T, Saeed M, Xu Z, Zhong F, Song R, Huai M, Zheng M, Xie C, Xu L, Yu H. Regulating Glucose Metabolism with Prodrug Nanoparticles for Promoting Photoimmunotherapy of Pancreatic Cancer. Adv Sci (Weinh) 2021;8:2002746. [PMID: 33643795 DOI: 10.1002/advs.202002746] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 27.0] [Reference Citation Analysis]
436 Brind'Amour A, Webb M, Parapini M, Sidéris L, Segedi M, Chung SW, Chartier-Plante S, Dubé P, Scudamore CH, Kim PTW. The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review. Clin Exp Metastasis 2021;38:187-96. [PMID: 33486670 DOI: 10.1007/s10585-021-10074-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
437 Menini S, Iacobini C, Vitale M, Pesce C, Pugliese G. Diabetes and Pancreatic Cancer-A Dangerous Liaison Relying on Carbonyl Stress. Cancers (Basel). 2021;13. [PMID: 33467038 DOI: 10.3390/cancers13020313] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
438 Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, Zhao F, You L, Zheng L, Zhang T, Zhao Y. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol 2021;14:14. [PMID: 33436044 DOI: 10.1186/s13045-020-01030-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 58] [Article Influence: 8.0] [Reference Citation Analysis]
439 Cusumano D, Boldrini L, Yadav P, Casà C, Lee SL, Romano A, Piras A, Chiloiro G, Placidi L, Catucci F, Votta C, Mattiucci GC, Indovina L, Gambacorta MA, Bassetti M, Valentini V. Delta Radiomics Analysis for Local Control Prediction in Pancreatic Cancer Patients Treated Using Magnetic Resonance Guided Radiotherapy. Diagnostics (Basel) 2021;11:72. [PMID: 33466307 DOI: 10.3390/diagnostics11010072] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
440 Khan T, Paul BK, Hasan MT, Islam MR, Arefin M, Ahmed K, Islam MK, Moni MA. Significant pathway and biomarker identification of pancreatic cancer associated lung cancer. Informatics in Medicine Unlocked 2021;25:100637. [DOI: 10.1016/j.imu.2021.100637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
441 Kong K, Zhao Y, Xia L, Jiang H, Xu M, Zheng J. B3GNT3: A prognostic biomarker associated with immune cell infiltration in pancreatic adenocarcinoma. Oncol Lett 2021;21:159. [PMID: 33552277 DOI: 10.3892/ol.2020.12420] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
442 Xu D, Wang Y, Zhou K, Wu J, Zhang Z, Zhang J, Yu Z, Liu L, Liu X, Li B, Zheng J. Identification of an extracellular vesicle-related gene signature in the prediction of pancreatic cancer clinical prognosis. Biosci Rep 2020;40:BSR20201087. [PMID: 33169793 DOI: 10.1042/BSR20201087] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
443 Nie Y, Zhao Z, Chen M, Ma F, Fan Y, Kang Y, Kang B, Wang C. Anillin is a prognostic factor and is correlated with genovariation in pancreatic cancer based on databases analysis. Oncol Lett 2021;21:107. [PMID: 33376540 DOI: 10.3892/ol.2020.12368] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
444 Villalobos-Ayala K, Ortiz Rivera I, Alvarez C, Husain K, DeLoach D, Krystal G, Hibbs ML, Jiang K, Ghansah T. Apigenin Increases SHIP-1 Expression, Promotes Tumoricidal Macrophages and Anti-Tumor Immune Responses in Murine Pancreatic Cancer. Cancers (Basel) 2020;12:E3631. [PMID: 33291556 DOI: 10.3390/cancers12123631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
445 Ahmed AA, Neidle S. A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells. Molecules 2020;25:E5407. [PMID: 33227941 DOI: 10.3390/molecules25225407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
446 Xie D, Qian B, Yang J, Peng X, Li Y, Hu T, Lu S, Chen X, Han Y. Can Elderly Patients With Pancreatic Cancer Gain Survival Advantages Through More Radical Surgeries? A SEER-Based Analysis. Front Oncol 2020;10:598048. [PMID: 33194764 DOI: 10.3389/fonc.2020.598048] [Reference Citation Analysis]
447 Iwai T, Yoshimura M, Ashida R, Goto Y, Kishi T, Itasaka S, Shibuya K, Kanai M, Masui T, Fukuda A, Isoda H, Hiraoka M, Mizowaki T. Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma. Radiat Oncol 2020;15:264. [PMID: 33187523 DOI: 10.1186/s13014-020-01712-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
448 Maeda N, Matsuda A, Otsuguro S, Takahashi M, Fujii M, Maenaka K. Antitumor Effect of Sugar-Modified Cytosine Nucleosides on Growth of Adult T-Cell Leukemia Cells in Mice. Vaccines (Basel) 2020;8:E658. [PMID: 33167425 DOI: 10.3390/vaccines8040658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
449 Randazzo O, Papini F, Mantini G, Gregori A, Parrino B, Liu DSK, Cascioferro S, Carbone D, Peters GJ, Frampton AE, Garajova I, Giovannetti E. "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer. Cancers (Basel) 2020;12:E3206. [PMID: 33142664 DOI: 10.3390/cancers12113206] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
450 Zou Y, Han H, Ruan S, Jian Z, Jin L, Zhang Y, Chen Z, Yin Z, Ma Z, Jin H, Dai M, Shi N. Development of a Nomogram to Predict Disease-Specific Survival for Patients After Resection of a Non-Metastatic Adenocarcinoma of the Pancreatic Body and Tail. Front Oncol 2020;10:526602. [PMID: 33194585 DOI: 10.3389/fonc.2020.526602] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
451 Zhang Y, Li Y, Wang Q, Su B, Xu H, Sun Y, Sun P, Li R, Peng X, Cai J. Role of RASA1 in cancer: A review and update (Review). Oncol Rep 2020;44:2386-96. [PMID: 33125148 DOI: 10.3892/or.2020.7807] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
452 Uehara M, Domoto T, Takenaka S, Bolidong D, Takeuchi O, Miyashita T, Minamoto T. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer. Cancer Sci 2020;111:4405-16. [PMID: 32986894 DOI: 10.1111/cas.14668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
453 Gao Y, Chen S, Vafaei S, Zhong X. Tumor-Infiltrating Immune Cell Signature Predicts the Prognosis and Chemosensitivity of Patients With Pancreatic Ductal Adenocarcinoma. Front Oncol 2020;10:557638. [PMID: 33102222 DOI: 10.3389/fonc.2020.557638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
454 Le H, To D, Tran M, Do T, Nguyen P. Natural PTP1B Inhibitors From Polygonum cuspidatum and Their 2-NBDG Uptake Stimulation. Natural Product Communications 2020;15:1934578X2096120. [DOI: 10.1177/1934578x20961201] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
455 Paoli C, Carrer A. Organotypic Culture of Acinar Cells for the Study of Pancreatic Cancer Initiation. Cancers (Basel) 2020;12:E2606. [PMID: 32932616 DOI: 10.3390/cancers12092606] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
456 Luo W, Tao J, Zheng L, Zhang T. Current epidemiology of pancreatic cancer: Challenges and opportunities. Chin J Cancer Res. 2020;32:705-719. [PMID: 33446994 DOI: 10.21147/j.issn.1000-9604.2020.06.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]